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What is a scientist after all?
It is a curious man looking through a keyhole,
the keyhole of nature, trying to know what?s going on.
-Jacques Cousteau-
?This is the strangest life I have ever known?
-Jim Morrison?
Hey?Ho, Let?s Go
-The Ramones-
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ABBREVIATIONS
AAV Adeno associated virus
CUB Clr/Cls, Urchin EGF-like protein and Bone
morphogenic protein 1
E embyonic day
EC endothelial cell
ECM extracellular matrix
Ig immunoglobulin
IFP interstitial fluid pressure
IHC immunohistochemistry
K14 keratin 14
kb kilo base pair
kDa kilodalton
LYVE-1 lymphatic vessel endothelial hyaluronan receptor-1
mAb monoclonal antibody
mRNA        messenger ribonucleid acid
PC pericyte
PCR polymerase chain reaction
PDGF          platelet-derived growth factor
PDGFR        platelet-derived growth factor receptor
PECAM-1  platelet endothelial cell adhesion molecule-1
PlGF            placenta growth factor
SMA smooth muscle actin
SMC smooth muscle cell
TK                tyrosine kinase
VEGF           vascular endothelial growth factor
VEGFR        vascular endothelial growth factor receptor
VSMC vascular smooth muscle cell
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ABSTRACT
Over the last decade or so, different angiogenic factors have been studied
intensively. Several factors have been associated with cancer growth and vascular
diseases, such as atherosclerosis. One of the most researched and important families
of growth factors has been the PDGF/VEGF family. PDGFs are major mitogens for
several cell types of mesenchymal origin, such as smooth muscle cells and
fibroblasts. In vascular formation during vasculogenesis and angiogenesis, pericytes
and vascular smooth muscle cells form a supporting structure around endothelial cell
tubes to complete the formation of functional blood vessels. Without these cells the
nacent vessels are leaky and vessels of both increased and decreased diameter are
seen. PDGFs have been identified as some of the most important mitogens and
chemoattractans to pericytes and vascular smooth muscle cells. For decades, only
two chains of PDGF were known, PDGF-A and PDGF-B and only a few years ago
two additional members of this family were discovered and named PDGF-C and
PDGF-D.
This study presents the cloning and characterization one of these novel members of
this family, PDGF-D. We have defined its receptor binding specifity, finding that it
binds both PDGF receptors, ? and ?. We have also elucidated its domain structure,
discovering that it and its closest relative PDGF-C have a CUB domain at the N-
terminal end of the propeptide, a domain that is lacking from the two other
members of the PDGF family. We have also solved the processing of PDGF-D,
from a latent propeptide tothe active protein, which requires proteolytical removal
of the CUB domain. We found out that PDGF-D is expressed in several normal and
tumor tissues. Finally, we have used mouse models to find out that when
overexpressed, PDGF-D is a strong recruiter of macrophages to tissues or wounded
areas. We were able to use PDGF-D in combination with a known angiogenic
factor, VEGF-E, to grow better functioning blood vasculature in mice.
This study addresses the basic questions concerning the nature of PDGF-D, and
gives clues about its probable role in pathological conditions, such as atherosclerosis
and wound healing. Our studies also suggest possible future uses of PDGF-D in e.g.
wound healing therapy or for growing of new, functional blood vessels to ischemic
tissues.
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REVIEW OF THE LITERATURE
THE DEVELOPMENT OF BLOOD VESSELS
Vasculogenesis and angiogenesis
The vascular system provides oxygen and nutrients to all proliferating or developing
tissues. During embryogenesis, the development of the vascular system occurs via
two processes, vasculogenesis and angiogenesis ?Figure 1?. Vasculogenesis involves
the differentiation of endothelial cells ?ECs? from mesoderm derived precursor cells,
the hemangioblasts ?Risau and Flamme 1995?. From these are derived the EC
precursors ?angioblasts? and the hematopoietic cell precursors. The hemangioblasts
form primary blood islands, in which the cells are divided into interior and
peripheral layers. Cells in the interior layer differentiate into hematopoietic stem
cells and the cells in the periphery  differentiate into angioblasts, which then cluster
and reorganize to form capillary-like tubes ?Asahara et al., 1997?.
After the primary vascular plexus is formed, new capillaries form by sprouting or by
splitting ?intussusception? from pre-existing vessels. This process is called
angiogenesis ?Figure 1??Risau, 1997?. Further remodelling occurs when new vessels
mature and form vessels of different sizes. Some vessels fuse to form larger ones
while some regress. In the primary capillary plexus the ECs start to differentiate
into arterial or venous type ?Yancopoulos et al., 1998?. Layers of pericytes and
vascular smooth muscle cells ?VSMCs? start to gather around newly formed EC
tubes.  Basal laminae form between the cells and provide further support to the new
vessels. In pathological angiogenesis, the maturation and stabilization of the vessels
occur improperly and the vessels remain immature ?Hashizume 2000; Shunichi
2002?. Angiogenesis is tightly regulated by intercellular signalling mechanisms,
growth factors and cytokines. For some time now, the induction of angiogenesis has
also been seen as a way of treating tissue ischemia ?reviewed in Ferrara et al., 2003?.
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Figure 1. Schematic illustration of vasculogenic and angiogenic processes
in developing embryos. In vasculogenesis, mesodermal cells first differentiate
into hemangioblasts, whereafter endoderm-mesoderm interactions are required for
further blood island differentiation ?Risau and Flamme, 1995?. After the formation
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of the primary capillary plexus, new vessels are generated via angiogenesis ?Risau,
1997?. During sprouting angiogenesis, ECs degrade the underlying basement
membrane, migrate, proliferate and reassemble into tubes. In non-sprouting
angiogenesis, new vessels are formed by intussusceptive growth or the existing
vessels increase in size through intercalated growth. The formed vasculature is
remodeled into a tree-like hierarchy, containing vessels of different sizes. When
excess branches are pruned, some vessels regress and others fuse to form larger
vessels. The vessels further mature by recruitment of pericytes and smooth muscle
cells. Formation of the extracellular matrix and particularly the basal lamina gives
support to the vessels. The most important growth factors or their receptors
mediating blood vessel growth and maturation are indicated on the right. EC=
endothelial cell, PC= pericyte, SMC= smooth muscle cell. Modified from ?Saaristo
et al., 2002? and ?Carmeliet and Collen, 2000?.
Endothelial cells
Endothelial cells are very diverse in their morphology, function and gene-expression
profiles. Morphologically, they differ in size, shape, thickness, number of microvilli,
and the position of the nucleus. For example, aortic endothelial cells are generally
thicker but cover a smaller area than those lining the pulmonary artery ?Conway and
Carmeliet, 2004?. ECs function in a variety of physiological situations, and therefore
the capillary endothelium of each individual normal tissue is highly specialized.
There are also results which show some specific EC markers that are present only in
tumor vasculature ?Arap et al., 1998?.
Pericytes and vascular smooth muscle cells
Pericytes and vascular smooth muscle cells ?VSCMs? form a supporting structure
around EC tubes to complete the formation of functional blood vessels. Without
these cells the forming vessels are leaky and vessel diameter varies extensively
?Hellstrom et al., 2001?. In the mature vascular system, arteries are surrounded by
VSMCs but smallest capillaries are only partially covered by pericytes. Vessels of
intermediate size, arterioles and venules, have cells that have properties of both
pericytes and VSMCs.
Pericytes and VSMCs originate from multiple sources including mesenchymal cells,
neural crest cells and epicardial cells ?Hungerford and Little, 1999?. In embryonic
mesodermal cells they have common progenitors with the ECs ?Flk-1 positive
embryonic stem cells?, which can differentiate into ECs in presence of vascular
endothelial factor ?VEGF? or into VSMCs in the presence of platelet-derived
growth factor B ?PDGF-B? ?Yamashita et al., 2000?. Pericytes and VSMCs are
closely related and they can interconvert into each other ?Nehls and Drenckhahn,
1993; Nicosia and Villaschi, 1995?. There are however, some major differences
between the two. Pericytes are adjacent to and surround the endothelium, share a
common basement membrane with the endothelium, and have gap-junction
connections with the endothelial cells. VSMCs  also surround ECs, but they do not
share the basal layer with them and do not have direct connection with ECs as
pericytes do.
The location of pericytes and VSMCs at the interface between the endothelium and
the surrounding tissue makes them ideally positioned to take an active part in the
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angiogenic process ?Allt and Lawrenson, 2001?. In many diseases involving
angiogenesis, such as tumour growth and diabetic retinopathy, inhibition of
pathological neovascularization is one possible treatment and recent results now
indicate pericytes as possible antiangiogenic targets ?Benjamin et al., 1999; Gee et
al., 2003?. On the other hand, pericytes and VSMCs are also coming into focus in
proangiogenic therapies, especially when there is a need to stabilize newly formed
vessels after successful neovascularization ?Cao et al., 2003; Dor et al., 2002;
Richardson et al., 2001?.
VASCULAR ENDOTHELIAL GROWTH FACTORS  AND THEIR
RECEPTORS
The VEGF family of growth factors consists of five polypetides ?VEGF-A, -B, -C, -
D and placenta growth factor, PlGF? which are able to bind variably to vascular
endothelial growth factor receptors ?VEGFR? 1, 2 and  3.
         
VEGF-A
VEGFR-1 VEGFR-2 VEGFR-3
VEGF-D
VEGF-C
VEGF-B
VEGF-E
PlGF
VEGF-A
VEGF-D
VEGF-C
 PDGF-D, a novel member of the PDGF family
13
Figure 2.  Receptor binding of VEGF family members. VEGFR-1 and
VEGFR-2 are predominantly expressed in the endothelium of blood vessels, and
VEGFR-3 in the endothelium of lymphatic vessels.
VEGF
VEGF ?or VEGF-A? is a major regulator of vasculogenesis and angiogenesis and
binds to and activates VEGFR-1 and VEGFR?2. VEGF is also known to induce
vascular permeability ?Senger et al., 1983? ?Dvorak et al., 1995?. VEGF is expressed as
several isoforms of different amino acid chain lengths ?VEGF121, VEGF145, VEGF165,
VEGF183, VEGF189, VEGF206??Ferrara et al., 2003?. Of these, VEGF165 seems to be
most efficent inductor of angiogenesis ?Stalmans et al., 2002?.VEGF is a highly
specific mitogen for vascular ECs ?Connolly et al., 1989; Ferrara and Davis-Smyth,
1997; Ferrara and Henzel, 1989; Leung et al., 1989; Plouet et al., 1989? and it is also a
survival factor for ECs, both in vitro and in vivo ?Alon et al., 1995; Gerber et al.,
1998?. Pericyte coverage of the new vessels has been proposed to be one of the
critical factors that determine the sensitivity of ECs to VEGF ?Benjamin et al.,
1999?. VEGF has also an effect on the blood cells; it can promote monocyte
chemotaxis and induce colony formation by mature granulocyte-macrophage
progenitor cells ?Clauss et al., 1990??Broxmeyer et al., 1995?. In the ischemic brain
VEGF exerts an acute neuroprotective effect, as well as longer latency effects on the
survival of new neurons ?Sun et al., 2003?.
VEGF-B
VEGF-B has two, differentially spliced isoforms, VEGF-B167 and VEGF186. The
more abundant in vivo form is VEGF-B167 ?Li and Eriksson, 2001; Olofsson et al.,
1996?. Its highest expression levels are found in brown fat, skeletal muscle and the
myocardium ?Olofsson et al., 1999?. The only VEGFR that VEGF-B activates is
VEGFR-1 ?Olofsson et al., 1998?. The function of VEGF-B has long been unclear,
and although it is abundant in some tumor types ?Salven et al., 1998? there has been
no conclusive evidence of its effects.
VEGF-C and VEGF-D
VEGF-C and VEGF-D are the two members of the VEGF family which are capable
of inducing the proliferation and migration of lymphatic endothelial cells in vitro and
growth of new lymphatic vessels in vivo ?Achen et al., 1998; Jeltsch et al., 1997;
Joukov et al., 1996; Makinen et al., 2001?. Unprocessed VEGF-C binds to VEGFR-3
but only the fully processed form can bind to and activate VEGFR-2 ?Joukov et al.,
1997?. Simnilarly, human VEGF-D can bind to and activate both VEGFR-2 and
VEGFR-3 when fully processed ?Achen et al., 1998?. At high concentrations these
fully processed factors can promote angiogenesis and increase vascular permeability,
although not as much as VEGF-A ?Joukov et al., 1997; Oh et al., 1997;
Witzenbichler et al., 1998?.
PlGF
Placenta growth factor ?PlGF? has three isoforms, PlGF-1, ?2 and ?3; all bind
specifically to VEGFR-1 ?Cao et al., 1997; Maglione et al., 1991; Maglione et al., 1993;
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Park et al., 1994?. PlGF can also form heterodimers with VEGF, and the
VEGF/PlGF heterodimers have been shown to bind to VEGFR-2  ?DiSalvo et al.,
1995?. PlGF homodimers are chemotactic for monocytes and ECs in vitro ?Clauss et
al., 1996? and PlGF is angiogenic and arteriogenic in vivo ?Pipp et al., 2003?. PlGF
may induce myocardial revascularization by amplifying the angiogenic activity of
VEGF, which is upregulated in the ischemic myocardium. In addition, PlGF may
stimulate myocardial angiogenesis by increasing VEGF expression by fibroblasts,
which are abundant in the myocardial stroma ?Luttun et al., 2002?.
VEGF-E
VEGF-E is sometimes included as a sixth member of the VEGF protein family. It is
a viral protein discovered from the genome of the Orf virus ?OV?, which is an
epitheliotropic parapoxvirus of cattle and sheep ?Cottone et al., 1998; Lyttle et al.,
1994?. Twenty four different forms of VEGF-E are known so far ?Mercer et al.,
2002?. Of these VEGF-E NZ-2, VEGF-E NZ-7 and VEGF-ED1701 are the best
characterized. These three forms all bind to VEGFR-2, all with essentially the same
activity ?Lyttle et al., 1994; Meyer et al., 1999; Wise et al., 1999?. Of these forms
VEGF-E NZ-7 has been most used in research so far. Overexpression of this factor
induces strong angiogenesis, although the quality of the newly made blood vessels is
poor ?Kiba et al., 2003? ?III?.
VEGFR-1
VEGFR-1 has seven immunoglobulin ?Ig? homology domains in the extracellular
part, a trans-membrane region and an intracellular tyrosine kinase ?TK? domain,
which is interrupted by a kinase-insert domain ?Matthews et al., 1991; Shibuya et al.,
1990; Terman et al., 1991?. It is present mostly in ECs and binds VEGF, PlGF ?Park
et al., 1994? and VEGF-B ?Olofsson et al., 1998?. An alternatively spliced form
producing soluble form of VEGFR-1 has been shown to inhibit VEGF activity
?Kendall and Thomas, 1993?. The precise function of VEGFR-1 is still debated, but
it has been implicated in negative regulation of VEGF activity ?Fong et al., 1999?.
VEGFR-1 phosphorylation is very weak in vitro after VEGF stimulation ?Seetharam
et al., 1995; Waltenberger et al., 1994?, and high concentrations of PlGF that
saturate the VEGFR-1 sites for binding, have been shown to potentiate the activity
of VEGF both in vivo and in vitro, suggesting that VEGFR-1 may act as a decoy
receptor for VEGF in the ECs, not primarily transmitting a mitogenic signal, but
rather binding VEGF to make it less available for VEGFR-2 ?Park et al., 1994?.
However, other results have indicated that VEGFR-1 is able to interact with various
signal-transducing proteins and generate a mitogenic signal ?Landgren et al., 1998;
Zeng et al., 2001?. In addition to ECs, VEGFR-1 is expressed in monocytes,
macrophages, pericytes, placental trophoblasts, renal mesangial cells and in some
bone marrow derived hematopoietic stem cells ?Barleon et al., 1994; Clauss et al.,
1996; Hattori et al., 2002; Ziegler et al., 1993?.
VEGFR-2
The structure of VEGFR-2 is similar to VEGFR-1, but VEGFR-2 binds VEGF,
VEGF-C, VEGF-D and viral VEGF-E. It is primarily present in ECs, but also
expressed in megakaryocytes, platelets, retinal progenitor cells, some hematopoietic
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stem cells and in circulating endothelial precursor cells ?Katoh et al., 1995; Ziegler et
al., 1999?. Although VEGFR-2 binds VEGF with lower affinity than VEGFR-1,
there is a general agreement that most of the biological effects of VEGF are
mediated via VEGFR-2. Receptor specific mutant forms of VEGF have been used
to show that VEGFR-2 is the major mediator of the mitogenic, angiogenic and
permeability- enhancing effects of VEGF and that EC survival is dependent on
VEGFR-2 ?Gerber et al., 1998; Gille et al., 2001; Keyt et al., 1996?.
VEGFR-3
VEGFR-3 is a receptor that binds VEGF-C and VEGF-D ?Achen et al., 1998;
Joukov et al., 1996?. Furthermore, the lymphangiogenic effects of VEGF-C and
VEGF-D are thought to be mediated via VEGFR-3 ?Veikkola et al., 2001?. VEGFR-
3 has only six immunoglobulin ?Ig??homology domains in the extracellular domain, a
transmembrane region and a tyrosine kinase ?TK? domain. Two different forms of
VEGFR-3 are expressed in humans. The long form is more abundant, the short form
having 65 amino acids less in its C-terminus ?Hughes 2001?.  During early vascular
development VEGFR-3 is expressed in the endothelium of the developing
vasculature, but when lymphatic vessels form, it is expressed almost exclusively in
the lymphatic endothelium ?Kaipainen et al., 1995?.
PLATELET?DERIVED GROWTH FACTORS
Platelet-derived growth factors ?PDGFs? are major mitogens for several cell types of
mesenchymal origin, such as smooth muscle cells and fibroblasts. Originally, PDGF
was identified as a constituent of whole blood serum that was absent in cell-free
plasma-derived serum ?Kohler and Lipton, 1974; Ross et al., 1974; Westermark and
Wasteson, 1976?. Not very long afterwards, PDGF was purified from human
platelets, thus gaining its name ?Antoniades et al., 1979; Heldin et al., 1979; Kaplan
et al., 1979?. Later it was discovered that PDGFs are synthesized by a number of
different cell types. PDGFs are composed of homo- and heterodimeric polypetide
chains. For a long time only two different chains were known, PDGF-A and PDGF-
B, the so called classic PDGFs. Later two additional chains were discovered, PDGF-
C ?Li et al., 2000? and PDGF-D ?I?, ?LaRochelle et al., 2001?. These four members
of the family bind to and activate two PDGF receptors, PDGFR-? and PDGFR-
?, which also form either homo- or heterodimeric complexes on the cell surface
after ligand binding.
PDGFs have a knot with eight cysteine residues that are conserved and present in
all four chains. It is known that in the two classical PDGFs, two of the cysteine
residues ?second and fourth? are involved in cysteine bonds between the two
subunits in the PDGF dimer, the other six are engaged in intrachain disulfide bonds
?Haniu et al., 1994; Haniu et al., 1993?. In the ?new? PDGFs, there are four extra
cysteine residues in PDGF-C and two extra ones in PDGF-D. At the moment it is
unclear what kind of effect these extra cysteins have on the three dimensional
structure of PDGF-C and PDGF-D.
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PDGF-A
The gene producing the PDGF-A chain is located on chromosome 7 ?Betsholtz et
al., 1986?. PDGF-A occurs as two different splice forms, producing mRNAs of 2.1
and 2.4 kb in length and encoding protein chains of 196 and 211 amino acid residues.
The gene has 7 exons, exon 1 encoding the signal sequence, exons 2 and 3 precursor
sequences that are removed during processing, while exons 4 and 5 encode most of
the mature PDGF-A protein. Exon 6 encodes a C-terminal sequence, which is
spliced out when the 211 aa splice form is produced. Exon 7 is mainly noncoding, but
has the stop-codon for the 196 aa form ?Bonthron et al., 1988?. PDGF-A is
synthesized and assembled into disulphide-linked dimers in the endoplasmic
reticulum, but to make it active, the N-terminal extension is cleaved and the mature
form activated in the exocytic pathway and then released into extracellular matrix
?Ostman et al., 1992?.  PDGF-AA binds to and activates only the PDGFR-
? homodimer. Several cell types express PDGF-A, e.g. fibroblasts ?Paulsson et al.,
1987?, VSMCs ?Nilsson et al., 1985; Paulsson et al., 1987?, ECs  ?Collins et al., 1987?,
macrophages ?Nagaoka et al., 1992? and astrocytes ?Noble et al., 1988; Richardson et
al., 1988?. At the tissue level the highest expression levels are found in the heart,
pancreas and skeletal muscle ?Fredriksson et al., 2004?.
Notably, PDGF-A also forms dimers with PDGF-B. PDGF-AB actually produces a
strong mitogenic and chemotactic effect on cells, especially in cells expressing both
? and ?  receptors ?Heidaran et al., 1990?.
PDGF-B
The gene producing the PDGF-B chain is located on chromosome 22 ?Dalla-Favera
et al., 1982; Swan et al., 1982?. PDGF-B gene produces mRNA of 3.5 kb in length and
encodes a protein chain 241 amino acids long. The structure of the gene is similar to
PDGF-A, except that exon 7 is completely noncoding. Exons 2 and 3 encode an N-
terminal part and exon 6 a C-terminal part that have to be proteolytically removed
before PDGF-B is activated ?Johnsson et al., 1984?. PDGF-B is produced and
cleaved in the exocytic pathway ?Ostman et al., 1992?. PDGF-Bs expression pattern
in different cell types is much like PDGF-As, it is expressed in several different cell
types, e.g. VSMCs ?Majesky et al., 1988?, ECs ?Hellstrom et al., 1999?, macrophages
?Ross et al., 1990? and fibroblasts ?Raines, 1991?. During development PDGF-B is
mostly expressed in the developing vasculature, where PDGF-B is produced by
endothelial cells ?Hellstrom et al., 1999?. At the tissue level in adults, most abundant
expression of PDGF-B is found from heart and placenta ?Fredriksson et al., 2004?.
PDGF-C
PDGF-C was the first of the two so called new PDGFs to be discovered. As with
the classical PDGFs, PDGF-C forms dimers, but only homodimers, which bind
primarily toPDGFR-? homodimer ?Li et al., 2000?, but there are reports showing
that it can activate also the PDGFR-?? heterodimer ?Cao et al., 2002; Gilbertson et
al., 2001?. The gene is located in the human chromosome 4, and, uniquely among the
PDGFs, has only 6 exons ?II?. The first exon encodes a signal sequence, while exons
2 and 3 encode an N-terminal CUB domain ?Clr/Cls, Urchin EGF-like protein and
bone morphogenic protein 1 ?Bork, 1991?. Exon 4 encodes the so called hinge area in
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front of the PDGF-homology domain, which is encoded by exons 5 and 6 ?II?. Full
length PDGF-C is 345 amino acids long and to make PDGF-C active, the N-
terminal CUB domain must be cleaved off proteolytically ?Li et al., 2000?. PDGF-C
mRNA is expressed in a variety of tissue types, most strongly in the heart, pancreas
and kidney ?Gilbertson et al., 2001; Li et al., 2000?. In human cell types PDGF-C
expression has been detected in VSMCs, ECs and fibroblasts ?II??Gilbertson et al.,
2001?.
Platelet?derived growth factor receptors
PDGF receptors are proteins which have five immunoglobulin-like extracellular
domains, a transmembrane domain and an intracellular tyrosine kinase domain
?Claesson-Welsh, 1989; Matsui et al., 1989; Yarden et al., 1986?. Since PDGFs are
dimeric molecules, they bind to two receptors simultaneously and thus dimerize the
receptors and become activated ?Bishayee et al., 1989; Heldin et al., 1989; Seifert,
1989?. The structures of the PDGFRs are similar to those of the colony stimulating
factor-1 ?CSF-1? receptor ?Coussens et al., 1986? and the stem cell factor ?SCF?
receptor ?Yarden et al., 1987?. The level of PDGF receptor expression on cell
surfaces is not constant, for instance during inflammation the levels of PDGFR-? on
connective tissue cells goes radically up ?Rubin et al., 1988?, and stimulation with
basic fibroblast growth factor or tumor necrosis factor ? selectively increases the
expression of PDGFR-? in VSMCs ?Schollmann et al., 1992; Sihvola et al., 1999?.
PDGFR-?
The human PDGFR-? gene is located on chromosome 4 ?Spritz et al., 1994?. It
binds and is activated by any of the following combinations of PDGF dimers;
PDGF-AA, PDGF-AB, PDGF-BB or PDGF-CC. Activation of PDGFR-?
transduces powerful mitogenic signals, and stimulates chemotaxis ?Hosang et al.,
1989; Shure et al., 1992? in certain cell types but is also claimed to inhibit chemotaxis
in other types, such as SMCs ?Siegbahn et al., 1990? ?Koyama et al., 1996??Yokote et
al., 1996?. The classic target cells for PDGFs such as fibroblasts and SMCs express
both receptor types, but there are some cell types which express only the other one.
O-2A glial precursor cells, human platelets and rat liver endothelial cells are cell
types known to express only PDGFR-? ?Hart et al., 1989; Heldin et al., 1991;
Vassbotn et al., 1994?. 
PDGFR-?
The human PDGFR-? gene is located in chromosome 5 ?Yarden et al., 1986?. It
binds to and is activated only by PDGF-BB and PDGF-DD. As is the case with
PDGFR-?,  activation of PDGFR-? is also source of powerful mitogenic signals and
chemotaxis ?Heldin and Westermark, 1996; Siegbahn et al., 1990?. PDGFR-?  also
mediates the formation of circular actin structures on the dorsal cell surface
?Eriksson et al., 1992?, whereas receptor ? does not. Fibroblasts and SMCs express
both receptors, but usually they express PDGFR-? at higher levels ?Heldin and
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Westermark, 1996?. The cellular expression pattern of PDGFR-? is mostly similar
to PDGFR-?, but some types of cells express only receptor ?. Such kinds of cell
types are, for example, certain capillary ECs, pericytes and mammary epithelial cells
?Bar et al., 1989; Smits et al., 1989; Sundberg et al., 1993; Taverna et al., 1991?.
PDGFs in development
Deletion of PDGF-A chain in mice leads to defective development of alveoli of the
lung, giving an emphysema-like phenotype. This is caused by the lack of distal
spreading of alveolar smooth muscle cell progenitors during lung development,
leading to death of the mice around 3 wk of age ?Bostr?m, 1996; Lindahl et al.,
1997b?. PDGFR-? deficient mice die during embryogenesis, the embryos displaying
cranial malformations and defiency of myotome formation ?Soriano, 1997?.
Genetically partially rescued PDGFR-?  null mouse chimeras display similar
phenotype to PDGF-A null mice ?Sun et al., 2000?. The expression patterns of
PDGF-A and PDGFR-? during lung development suggest a paracrine pattern,
where PDGF-A is expressed by the epithelium and PDGFR-? by populations of
adjacent mesenchymal cells ?Bostr?m, 1996; Lindahl et al., 1997b?. PDGF-A
deficient mice display also a reduced number of intestinal villi, showing abnormaily
in their length and thickness ?Karlsson et al., 2000?. During intestinal development
PDGF-A is initially expressed in the intestinal epithelium whereas PDGFR-? is
expressed in proliferating meenchymal cells immediately subjacent to the epithelium
?Karlsson et al., 2000?. The loss of PDGF-A results in failure of PDGFR-? positive
cells to localize properly in the gut ?Karlsson et al., 2000?. This would indicate that
the role of PDGF-A in the development of the gut would be to secure the
placement of the PDGFR-? positive mesenchymal cells. The PDGF-A null mice
also developed a tremor due to severe hypomyelination of the neuronal projections
within the central neural system ?CNS? ?Fruttiger et al., 1999?.
Although PDGF-B binds to all three receptor-dimers, during development it seems
to act mostly via PDGFR-? homodimers. This conclusion has been made mostly by
comparing the knock-out models where the deletion of PDGF-B or PDGFR-? has
quite similar effects. The knock-out mice die at embryonic stage from widespread
microvascular bleedings ?Lev?en, 1994?. This is caused by a severe shortage of
VSMCs and pericytes ?Lindahl et al., 1997a?. In both types of mice the mesangial
cells are almost completely missing ?Lev?en, 1994; Soriano, 1994?. This leads to poor
filtration in the glomeruli. In the process of mesangial cell recruitment, ECs express
PDGF-B and mesangial cells PDGFR-?, suggesting paracrine signaling similar to
that in capillary formation elsewhere ?Lindahl et al., 1998?. In contrast to PDGFR-?
null mice, the PDGF-B null mice had also heart defects with an increased size and
trabeculation of the myocardium. The fact that this is not detected in the PDGFR-
? null mice indicates that in the heart PDGF-BB may act via PDGFR-?.
The roles of the PDGF-C and PDGF-D in embryonic development are still not
known, although the close similarities between the PDGF-B and PDGFR-? null
phenotypes make it difficult to envision a role for PDGF-D as a developmental
ligand for PDGFR-?. Such is not the case with PDGF-A and PDGFR-?. As PDGF-
B does not explain the differences either, the remaining candidate is PDGF-C ?Li et
al., 2000?. Some still unpublished results from PDGF-C null mice have indeed given
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an indication that PDGF-C has partially overlapping functions with these two other
ligands ?Betsholtz, 2004?.
PDGFs in disease and treatment
PDGFs in tumors and tumor therapy
Two decades ago, the transforming gene in Simian Sarcoma Virus, sis, was found to
encode PDGF-B ?Doolittle et al., 1983; Waterfield et al., 1983?. Since then PDGF
overactivity has been associated with several cancer types. In gliomas and
astrocytomas PDGFs and PDGFRs are upregulated in an autocrine manner and
their expression levels are higher in advanced forms of gliomas than in less
malignant tumors ?Hermanson et al., 1992; Hermanson et al., 1996?. On the other
hand, ininvasive gastric carcinomas PDGF-A has been found to provide an effective
prognostic marker because high levels of PDGF-A correlate with high grade
carcinomas ?Nakamura et al., 1997??Katano et al., 1998?. The new PDGFs have also
been associated with some tumors, PDGF-C with Ewing carcinomas ?Zwerner and
May, 2001? and PDGF-D with e.g. ovarian and lung cancer ?LaRochelle et al., 2002?.
In development of anti-cancer therapies PDGFs and their receptors are beginning
to draw more attention. Especially PDGFR-? in pericytes constitutes a relevant
target for anti-cancer therapy. This based on results, according to which the
lowering of the the interstitial pressure of the tumor helps the access of
chemotherapeutic drugs to the tumors  and thus enhances their effects ?Pietras et
al., 2002?. This was obtained mostly by inhibiting the function of PDGFR-
? inside the tumor  using the new PDGF receptor blocker, STU571 i.e. Glivec
?Pietras et al., 2001?. Such therapy, combined with for example the new anti-
angiogenic drugs, like Bevacizumab ?Avastin?, Genentech? which is an anti-VEGF
monoclonal antibody ?Yang et al., 2003?, can prove to be very effective in treatment
of solid tumors.
PDGFs in cardiovascular disease
Atherosclerosis is a complex, largely inflammatory response in large and medium
arteries to a number of different risk factors that results in an accumulation of cells
and extracellular matrix in the intimal space ?Ross, 1999?. One central player in the
forming of the atherosclerosis is the macrophage. Accumulation of macrophages is
the first cellular event in lesion initiation, and they are present throughout the
stages of lesion development. In fact, reducing macrophage recruitment can
decrease lesion development ?Boring et al., 1998; Ni et al., 2001?.
PDGFs and their receptors are expressed at low levels in normal vessels, but the
situation changes when atherosclerotic lesions start to form. The lesions
demonstrate increased levels of PDGF-B compared to normal vessels ?Barrett and
Benditt, 1987?, and the macrophages at the scene express both PDGF-A and PDGF-
B ?Evanko et al., 1998?. Expression of PDGF-C and PDGF-D by macrophages has
not been reported. PDGF receptor ? expression is also increased in atherosclerotic
lesions, most of the expression being in SMCs ?Rubin et al., 1988? with more
localized expression in macrophages ?Tanizawa et al., 1996?. Elevated PDGF
receptor ? expression has been detected in atherosclerosis, and also from renal
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arterosclerosis ?Floege et al., 1998; Giese et al., 1999; Sihvola et al., 1999?. The
involvement of PDGFs has been tested in several animal models, for example by
using balloon catheterization of rat carotid arteries. In the denuded artery, there is
an increase of activated PDGF receptors in the vessel wall ?Abe et al., 1997; Panek et
al., 1997?. The initial thickening of the vessel wall that follows this treatment was
inhibited with PDGF antibodies ?Ferns et al., 1991?. Furthermore, infused PDGF-
BB into the rat carotid artery following a denudation caused significant thickening
of the lesion area compared to non-treated animals ?Jawien et al., 1992?.
The blocking of PDGFs or their receptors as a form of treatment in atherosclerosis
was tested some time ago and inhibitors of PDGF-B or PDGFR-?  to stop
SMC/pericyte accumulation gave some positive results ?Maresta et al., 1994?.
Another side to the story is the possible use of PDGFs to help create new blood
vessels after atherosclerosis has created an ischemic area. PDGFs are not very
angiogenic, but they are very important factors in recruiting SMCs and pericytes
around new vessels, therefore the combinations of PDGFs with some effective
angiogenic factors may turn out to be very useful.
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AIMS OF THE STUDY
Specific aims of the study:
I  To clone and characterize a novel growth factor, PDGF?D, to find out
its amino acid sequence, domain structure, receptor binding and
activating properties as well as tissue expression.
II  To find the exon?intron structure, chromosomal localization of PDGF?
D and its expression in normal cells and various types of tumor cells.
III To investigate the potential of PDGF?D in treating certain diseases; in
wound healing and growing of new, functional blood vessels in
combination with angiogenic factors.
IV To verify the receptor binding properties of PDGF?D, to clarify the
processing   site and to explore the function and significance of the CUB
domain in PDGF?D.
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MATERIALS AND METHODS
The materials and methods are described in detail in the original publications,
which are here referred to using Roman numerals.
The cloning of PDGF?D cDNA  ?I?
The PDGF-D cDNA was originally identified from NCBI EST database, cloned
with PCR from a human fetal lung 5?-STRETCH PLUS ?gt10 cDNA library
?Clontech?. The PCR fragment was labelled to high specific activity by random
priming ?Amersham Inc.? and the same cDNA library was screened by plaque
hybridisation to isolate several partial cDNA clones. The longest subcloned insert
was 1934 bp in length and encoded the C-terminal of PDGF-D while the 5´-part was
missing. The 5´-part of the cDNA was then amplified by Rapid Amplification of
cDNA Ends ?RACE? using human heart cDNA as the template ?Clontech?.
mRNA expression of PDGF?D in human tissues, cell lines and tumor cell
lines ?I, II?
To test the mRNA expression levels of PDGF-D in human tissues, a human
Multiple Tissue Northern blot ?Clontech? was hybridised with the 32P-labeled 327 bp
PCR fragment of PDGF-D cDNA. A full length PDGF-B cDNA was used as
control probe.
Human umbilical vein and microvascular endothelial cells and coronary artery SMCs
were obtained from Promocell and cultured in passage 2-5, as recommended by the
supplier. The Wi-38 fetal lung fibroblasts and human tumor cell lines were obtained
from American Type Culture Collection. The isolation of polyadenylated RNA was
by oligo-dT cellulose chromatography; 5 µg was electrophoresed in agarose gels
containing formaldehyde, blotted onto Hybond-N filters ?Amersham?, which were
hybridized with PDGFC and PDGFD cDNA fragments. These were used to find the
expression levels of PDGF-D mRNA in endothelial- and smooth muscle cells and in
different tumor cell lines.
PDGF?D expression in mouse sections ?I, II?
For immunohistochemistry, affinity-purified rabbit antibodies to human PDGF-D
were applied onto tissue sections prepared from paraformaldehyde-fixed and
paraffin-embedded mouse embryos.
Production and receptor binding properties of PDGF?D protein ?I, II, IV?
Several different methods for producing the PDGF-D protein were used. For the
receptor-Ig binding experiments only a small amount of metabolically labelled
protein was needed, so PDGF-D expression plasmid was transfected into 293T cells
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and the conditioned medium was collected and used for immunoprecipitation with
receptor-Ig proteins ?PDGFR-?-Ig and PDGFR-?-Ig, R&D?.
To test the receptor competition assay a large amount of purified PDGF-D protein
was needed. This was produced in baculoviral system and checked with SDS-PAGE
under reducing conditions, followed by western blot analysis using the antipeptide
antiserum. The ligand competition binding experiments were carried out using
porcine aortic endothelial ?PAE? cells expressing human PDGFR-? or PDGFR-?.
Analysis of genetic structure and chromosomal location  of PDGFD ?II?
To analyze the exon-intron organization of PDGFC and PDGFD, human genomic
clones for the genes were isolated by PCR-based screening from P1 bacteriophage
and P1 artificial chromosome ?PAC? human diploid genome libraries ?Genome
Systems?. Genomic organization of PDGFC  and PDGFD  was determined by
sequencing the whole coding sequence and identifying the exon-intron junctions
from the genomic clones.
To find out the chromosomal location of PDGFD gene, fluorescense in situ
hybridization ?FISH? was used. Genomic DNA clones were nick-translated with
biotin 11-dUTP ?Sigma? and hybridized on metaphase chromosomes derived from
normal human peripheral blood lymphocytes, which were treated with5-
bromodeoxyuridine ?BrdU? at early replicating phase to induce banding pattern ?10?.
A multicolor image analysis was used for the acquisition, display and quantification
of the hybridization signals. The identification of the chromosomes was based on
4?,6?-diamino-2-phenylindole banding pattern which resembles G-bands after BrdU
incorporation at the early replicating phase.
Generation and analysis of transgenic K14?PDGF?D mice ?III?
Human PDGF-D cDNA ?bp 176 - 1285; Genbank sequence number: AF336376? was
inserted into the K14 promoter expression vector. The resulting construct was
digested to separate the expression cassette from the rest of the plasmid and
purified. A 5 ng/ml solution of the DNA was injected into fertilized eggs of the
FVB/n-strain of mice and the resulting transgenic mice were maintained in this
strain. For analysis of PDGF-D mRNA expression in the skin of transgenic and wild
type littermate mice, tissues were snap-frozen in liquid nitrogen and homogenized
with a dismembrator. Total RNA was extracted with the RNEasy Kit ?QIAGEN
GmbH, http://www1.qiagen.com?. Using the RNA a northern blot was made and
hybridized with a human PDGF-D probe. Protein expression was verified by
immunohistochemistry, by staining with antibodies against human PDGF-D. Two
transgenic lines were used for the analysis, with similar results.
The skin of the transgenic mice and their wild type littermates was removed, fixed
in paraformaldehyde and paraffin embedded. Some skin samples were snap-frozen in
liquid nitrogen and embedded in Tissue-Tek OCT- compound ?Sakura-Finetek
Europe BV, http://www.sakuraeu.com?.  Sections from these samples were stained
with markers for blood vessels ?PECAM-1?, lymphatic vessels ?VEGFR-3 and
LYVE-1?, hematopoietic cells ?CD45?, T-lymphocytes ?CD3?, B-lymphocytes ?B-
220?, granulocytes ?Ly-6G? and macrophages ?F4/80?. Measurement of interstitial
fluid pressure from the skin of seven transgenic and seven wild type mice was carried
out by using the modified Wick technique. To analyse the vessels from a wider area
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of the skin, the ears of the transgenic and wild type littermate mice were also whole
mount stained with antibodies against PECAM-1, LYVE-1 and smooth muscle
actin.
Wound healing experiments on K14?PDGF?D mice ?III?
One reason for creating the K14-PDGF-D transgenic mouse line was to investigate
the possible participation and effect of PDGF-D in the wound healing process. Two
circular wounds were made on both sides of the back with a 5 mm punch-biopsy
tool. The wounds were allowed to heal for up to 10 days, after which the mice were
sacrificed and the wounds were collected. Sections were stained with haematoxylin
and eosin.  The wound area was quantified by measuring the distance between the
edges of the migrating epidermis and dividing it with that of the original wound,
measured here as the distance between the edges of the panniculus carnosus muscle
layer. Sections were stained for blood- and lymphatic vessels and hemtopoietic cells.
To evaluate connective tissue amount from the wounds, sections were also stained
with Van Gieson?s stain and Masson?s Trichrome stain.
Production and use of AAVs ?III?
To investigate the effect of strong local overexpression of PDGF-D alone and when
combined with a known angiogenic factor, we created adeno-associated viruses
producing various growth factors. The full length VEGF-E ?bp 1- 399, Genbank
AF106020?, the full length PDGF-D ?PDGF-DFL?, and a short form ?PDGF-D?N,
bp 917-1285? as well as full length PDGF-B ?bp 1023-2368, GenBank NM_002608?
and human serum albumin ?HSA, bp 112- 1866, Genbank NM_000477? cDNAs were
cloned into the psub-CMV-WPRE plasmid. The recombinant AAVs were
produced as described before ?Karkkainen et al., 2001?. 50 µl of purified AAV ?5
x1011 genomic particles/ml? was injected into the subcutis of the ear or
gastrocnemius muscle of FVB or NMRI nude mice. Four weeks later the mice were
sacrificed and the tissues were analyzed similarily to the samples from K14-PDGF-D
transgenic mice.
The AAV-injected mice were also used in the vessel permeability test, where FITC-
Dextran was injected intravenously into the mouse tail vein. The ears were
monitored under a fluorescence microscope and pictures exposed for equal time
periods were taken after 1, 2 and 4 minutes.
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RESULTS AND DISCUSSION
1. The cloning and characterization of human PDGF?D ?I, IV?
We identified PDGF-D as a human expressed sequence tag ?EST? in a BLAST
search of the National Center for Biotechnology Information EST database. The
EST sequence was compared to the sequence of PDGF-C and an identity of
approximately 50% between them was detected. Several cDNA clones were isolated
but the 5´end of the complete coding region was lacking and using rapid
amplification of cDNA ends ?RACE? I was able to generate the missing part. The
full length cDNA of PDGF-D encodes a polypetide which is 370 amino acids long.
It has a signal sequence ?residues 1-22? and two domains, an N-terminal CUB
domain ?residues 56-167? and a C-terminal PDGF/VEGF-homology domain
?residues 272-362?, which also has the highest identity with the other members of the
PDGF/VEGF-family ?Figure 3?, especially PDGF-C ??50% identity?. Only seven of
the eight invariant cysteine residues found in other PDGF/VEGF domains are
present in PDGF-D, the fifth being replaced by glycine residue. Like PDGF-C,
PDGF-D also has an insertion of three amino acid residues between the conserved
cysteine residues, three and four, being the residues NCG in the case of PDGF-D.
This feature among others shows that PDGF-C and PDGF-D form their own
closely related subgroup in the PDGF/VEGF family ?Figure 4?.
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Figure  3. Alignment of the amino-acid sequences of members of the
PDGF/VEGF family, in which the regions that encompass the conserved cysteine
rich domain are shown. Identical residues to those in PDGF-D are boxed. The fifth
invariant cysteine residue in PDGF-D is replaced by glycine.
PlGF
VEGF
VEGF-B
VEGF-C
VEGF-D
PDGF-C
PDGF-D
PDGF-A
PDGF-B
102030405060
Figure 4. The dendrogram comparison of the growth?factor homology
domains in the PDGF/VEGF family. PDGF-C and PDGF-D form a subgroup
of the PDGFs. Numbers show substitutions per 100 residues.
C T P R N Y S V N I R E E L - K L A N V V F - - F P R C L L V Q R C G G N C G C 1 PDGF-D
C T P R N F S V S I R E E L - K R T D T I F - - W P G C L L V K R C G G N C A C 1 PDGF-C
C K T R T V I Y E I P R S Q V D P T S A N F L I W P P C V E V K R C T G - - - C 1 PDGF-A
C K T R T E V F E I S R R L I D R T N A N F L V W P P C V E V Q R C S G - - - C 1 PDGF-B
C H P I E T L V D I F Q E Y P D E I E Y I F K - - P S C V P L M R C G G - - - C 1 VEGF
C R A L E R L V D V V S E Y P S E V E H M F S - - P S C V S L L R C T G - - - C 1 PlGF
C Q P R E V V V P L T V E L M G T V A K Q L V - - P S C V T V Q R C G G - - - C 1 VEGF-B
C M P R E V C I D V G K E F G V A T N T F F K - - P P C V S V Y R C G G - - - C 1 VEGF-C
C S P R E T C V E V A S E L G K S T N T F F K - - P P C V N V F R C G G - - - C 1 VEGF-D
G T V N W R S C T C N S G K T V K K Y H E V L Q F E P G H I K R R G R A K T M A 38 PDGF-D
C L H N C N E C Q C V P S K V T K K Y H E V L Q L R P - - - K T G V R G L H K S 38 PDGF-C
C N T - - S S V K C Q P S R V H H R S V K V A K V E Y V R K K P K L K - - - - - 38 PDGF-A
C N N - - R N V Q C R P T Q V Q L R P V Q V R K I E I V R K K P I F K - - - - - 38 PDGF-B
C N D - - E G L E C V P T E E S N I T M Q I M R I K - P - - H Q G Q H - - - - - 36 VEGF
C G D - - E N L H C V P V E T A N V T M Q L L K I R - S - - G D R P S - - - - - 36 PlGF
C P D - - D G L E C V P T G Q H Q V R M Q I L M I R - - - - Y P S S Q - - - - - 36 VEGF-B
C N S - - E G L Q C M N T S T S Y L S K T L F E I T - V P L S Q G P K - - - - - 36 VEGF-C
C N E - - E S L I C M N T S T S Y I S K Q L F E I S - V P L T S V P E - - - - - 36 VEGF-D
L V D I Q L D H H E R C D C                                                     78 PDGF-D
L T D V A L E H H E E C D C                                                     75 PDGF-C
E V Q V R L E E H L E C A C                                                     71 PDGF-A
K A T V T L E D H L A C K C                                                     71 PDGF-B
I G E M S F L Q H N K C E C                                                     66 VEGF
Y V E L T F S Q H V R C E C                                                     66 PlGF
L G E M S L E E H S Q C E C                                                     65 VEGF-B
P V T I S F A N H T S C R C                                                     68 VEGF-C
L V P V K V A N H T G C K C                                                     68 VEGF-D
Decoration 'Decoration #1': Shade (with solid bright yellow) residues that match 
PDGF-D exactly.
Decoration 'Decoration #2': Box residues that match PDGF-D exactly.
 PDGF-D, a novel member of the PDGF family
27
We expressed the full length form of PDGF-D containing a C-terminal six-histidine
tag, the purified protein was shown to be 55 kDa under reducing and 90 kDa under
non-reducing conditions, therefore showing that it is composed of homodimers. It
is well documented that full length PDGF-C needs proteolytic processing to remove
the CUB domain and release the active PDGF/VEGF homology domain ?core
domain? which then interacts with the receptor. We could not identify a natural
enzyme which would remove the CUB domain from PDGF-D, but in the presence
of serum, PDGF-D underwent proteolytic processing to generate the active growth
factor dimer of the 23 kD PDGF homology domains, but lacking the N-terminal
CUB domains. To produce enough active protein for our receptor binding
experiments,  we generated a mutated form of PDGF-D. This form included factor
Xa cleavage sites ?IEGRx2, replacing residues 251-258, including the predicted
cleavage site, RKS/K?. When produced in insect cells, this form showed similar
properties in SDS-PAGE to wild-type PDGF-D, under both reducing and non-
reducing conditions. This protein was used in PDGF receptor binding experiment,
which showed that PDGF-D activates only PDGFR-?. However, other publications
claimed that PDGF-D would also bind and activate PDGFR?/? heterodimers
?LaRochelle et al., 2001?.
When PDGFR-?-Ig fusion protein became available, we decided to test this
binding again. This time we produced PDGF-D in mammalian cells in the presence
of serum. Suprisingly we noticed that the processed growth factor domain cleaved
from the full-length PDGF-D bound to both PDGFR-?-Ig and PDGFR-?-Ig. We
produced also another PDGF-D protein called PDGF-D?N, starting from the
amino acid 248, 9 amino acids before the predicted cleavage site ?RKS/K?. This
PDGF-D?N polypeptide lacking the CUB domain but containing part of the
intervening sequences was not proteolytically processed anymore and bound to
PDGFR-? but only very weakly to the PDGFR-?. Another produced protein was
the CUB domain with the whole intervening sequence before PDGF-homology
domain. This did not bind to either PDGF receptor, as expected. When co-
expressed, CUB domain formed a dimer with the naturally matured PDGF-D and
almost totally prevented its binding to PDGFR-?, but did not have any effect on
the binding of PDGF-D to PDGFR-?.
Because the ?N form of PDGF-D lacking the CUB domain was not proteolytically
processed at the cleavage site, we wanted to see if the CUB domain can transfer the
cleavage function to another homologous protein. We therefore made a PDGF-D-
VEGF chimeric protein, where the growth factor domain of VEGF was fused to the
N-terminal part of the PDGF-D polypeptide containing the CUB domain so that
the presumed cleavage site was preserved. The chimeric protein was cleaved in
between the CUB domain and VEGF domain and detailed analysis of the various
fusions showed that the cleavage was strongly inhibited when the N-terminal
PDGF-D sequence was further truncated so that the tribasic sequence RKSK was
partly deleted. This suggested that the major cleavage site in the chimeric protein is
located in this sequence.
When the chimeric proteins were analysed in nonreducing conditions, very little of
the homodimeric cleaved VEGF protein could be detected in the gels. Instead, the
major species of the CUB-VEGF protein were the full-length dimer and a
heterodimer formed between the full-length and cleaved CUB-VEGF chimera. This
suggests that the first cleavage separating the N-terminal CUB domain of PDGF-D
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and the VEGF domain is efficient, but the second cleavage is much more inefficient
after the loss of the first CUB domain. All forms bound to VEGFR-1 and VEGFR-
2, indicating that the CUB domain does not transfer the latency to VEGF. The co-
transfection of the PDGF-D and CUB-VEGF vectors led to heterodimerization of
the polypeptides. This co-transfection also had similar effect as co-transfection with
just the CUB domain, namely the binding of mature PDGF-D to PDGFR-? was
mostly prevented while there was no effect on the PDGFR-? binding.
 These results show that PDGF-D is indeed a dimer forming member of the
PDGF/VEGF protein family, and that it is a very close relative to PDGF-C,
described only one year earlier ?Li et al., 2000?. We show also that the role of the
CUB domain is of great importance in activation of the PDGF-D; it has to be
removed before the PDGF-D dimer can bind to and activate its receptor. We do
not yet know which enzymes are responsible for the processing in vivo. The
discovery that the fully processed PDGF-D binds to both PDGFR-?  and -? ,
although PDGF-D was first identified as PDGFR-? specific ligand with no affinity
towards PDGFR-? suggests new possible functions for PDGF-D, as PDGFR-?  is
expressed in some cell types that do not contain  PDGFR-?, such as astrocytes.
Although full length PDGF-D is unable to activate PDGFR-?, there is the
interesting possibility of formation of the full length PDGF-D-core domain PDGF-
D dimer, which could bind to the receptor as a monovalent ligand and act as an
antagonist. The tissue expression pattern seems to be similar to that of PDGF-B,
but there are also some differences, suggesting the possibility that in some tissues
PDGF-D might even be the primary ligand for PDGFR-?.
When searching the more exact role for the CUB-domain in PDGF-D, our results
indicated that the CUB domain does not mask receptor binding epitopes in a CUB-
VEGF chimeric factor, although such chimera blocked PDGF-D binding to
PDGFR-? and formed heterodimers with PDGF-D. The chimeras formed dimers
not only with each other, but also with full length PDGF-D, demonstrating that
CUB-domains regulate dimer formation specificity. Interestingly, a small amount of
heterodimers was also detected, which included one processed polypeptide and
another one, which was full length.
While previous studies showed that unprocessed PDGF-D has no receptor binding
activity, our experiments employing the various recombinant PDGF-D proteins
indicate that the ability of the N-terminally fused CUB domain to inhibit receptor
binding cannot be transferred to the related VEGF growth factor. CUB-VEGFs as
well as CUB domain alone seems to block PDGF-D binding to PDGFR-? but not
to PDGFR-?. This specificity may reflect the fact that the affinity of PDGF-D to
PDGFR-? is lower than to PDGFR-?, and thus more easily disturbed. This raises
also the question of the role of the CUB-domain cut loose during the processing of
PDGF-D. Could it have some kind of blocking effect, binding to full length PDGF-
D, forming heterodimers and blocking further processing? This would also provide
some explanation to the functional role of an alternatively spliced form of PDGF-D
which has no PDGF-homology domain. This splice form has been cloned from
mice, but not yet from humans ??Zhuo et al., 2003?, our unpublished data?. This
would also explain the fact that when expressed in mammalian cells, always almost
exactly half of the full length PDGF-D is processed to mature form and the other
half stays intact.
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PDGF-AA
PDGF-AB
PDGF-BB
PDGF-CC
PDGF-DD
PDGF-BB
PDGF-DDPDGF-DD
PDGF-AB
α βα ββα
PDGF-BB
PDGF-CC
Figure 5. Binding of PDGFs to PDGFRs. PDGFRs can form homo- and
heterodimers. PDGFs form five different dimeric isoforms.
2. The structure, chromosomal location and expression patterns of human
PDGFD gene ?I, II?
We obtained human genomic clones of PDGFC and PDGFD from PCR based
screening of P1 artificial chromosome libraries. By sequencing these clones we were
able to determine the exon/intron structure of both genes ?Figure 6?. PDGFD
consists of 7 exons, PDGFC of 6. Both genes start with a long untranslated sequence
in exon 1, which also encodes the signal peptide. Exons 2 and 3 encode the CUB
domain and are ?  58% identical. Exons 6 and 7 of PDGFD encode the
PDGF/VEGF homology domain and are ? 57% identical with PDGFC exons 5 and
6, which encode the homology domain. The main difference between the otherwise
closely related sequences is exon 4 of PDGFD, which contains sequences that
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cannot be identified in PDGFC. This exon encodes residues which are part of the
hinge area between the CUB domain and the PDGF/VEGF homology domain. The
rest of the hinge region is encoded by exon 5 ?exon 4 in PDGFC?. This part of the
hinge region contains a conserved basic sequence motif RKS/K, which may be one
of the targets of proteolytic cleavage needed for releasing of the active form of
PDGF-D.
208 218118 114181196Coding bp
STOP(370)ATG
124 205 181 63 199 215
CCCCGC CC
1 2 3 4 5 6 7
PDGFD
123
STOP (345)ATG
Exon 1 2 3 4 5
PDGFC
CCCCCC CC
6
Figure 6. The genomic organization of PDGFC and PDGFD. Exons shown
are numbered and the length of each coding sequence is marked in bp. Start ?ATG?
and stop codons and polypetide lengths are marked. Signal sequences ?SS? are shown
in blue, CUB domains in green and PDGF/VEGF homology domains in red.
Genomic clones were also used to find the chromosomal locations of PDGFD and
PDGFC genes. PDGFD was localized to human chromosome 11q22.3 to 23.1 and
PDGFC to 4q32.
The vascular expression patterns of these novel genes were investigated using
antibodiesgenerated against them, and signals from PDGF-D were detected in the
advetitial connective tissue layer of the suprarenal artery, while PDGF-C was
present in the smooth muscle cell ?SMC? layer. This result was consistent with the
expression patterns in cultured SMCs and fibroblasts.
We analysed the expression of PDGF-D mRNA transcripts in several human tissues
by northern blotting. This showed an approximately 4.0 kb transcript, highest
expression levels occurring in heart, pancreas and ovary. Slightly lower expression
levels were present in the placenta, liver, kidney, prostate, testis, small intestine,
spleen, thymus, colon and peripheral blood leucocytes. No expression was detected
in the brain, lung or skeletal muscle.
 Tissue expression of PDGF-D was also investigated immunohistochemically in
developing mouse embryos during mid-gestation ?E14.5?. This showed PDGF-D
expression in several tissues, including the developing heart and kidneys. In the
developing kidney we observed a strong staining of the fibrous capsule that
surrounds the embryonic kidney and the metanephric mesenchyme of the cortex.
We also found that these novel PDGFs are expressed in several tumor cell lines.
The 4.0 kb transcript of PDGF-D was present most strongly in a lung alveolar
carcinoma and in breast and prostate carcinoma cell lines.
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Because of the involvement of the PDGFs in blood vessel development and in the
pathogenesis of arteriosclerosis ?Betsholtz and Raines, 1997; Ross, 1993?, it was of
interest to find expression of the PDGF-C and PDGF-D mRNAs in cultured
microvascular endothelial cells. PDGF-D was found in the adventitial connective
tissue surrounding the suprarenal artery, suggesting that it provides a paracrine
ligand for the arterial SMCs. The biological activity of recombinant PDGF-C and
PDGF-D was confirmed in human coronary artery SMC cultures, where both of
these factors stimulated cell proliferation/survival. In previous studies, both PDGF-
A, which transduces signals via PDGFR-?, and PDGF-B, which transduces signals
via both PDGFR-?, PDGFR-? and via their heterodimers have been shown to
mediate SMC proliferation stimuli. Several antagonists specific for PDGF or its
receptors have recently been developed and shown to inhibit intimal hyperplasia
formation in various animal models, predominantly via increased SMC apoptosis
and possibly also via interference with SMC migration ?Leppanen et al., 2000?. Thus
it can be speculated that via their ability to stimulate the PDGFRs, PDGF-C and
PDGF-D could also be involved in the intimal SMC accumulation in
arteriosclerosis.
The role of PDGF-D in the course of embryogenesis is still to be deduced, and will
remain so until the knock-out model is complete and analysed. Our results show
that it is expressed during embryogenesis and has a likely a role during the
development of the heart and kidney.
The PDGF-C and PDGF-D mRNAs were also expressed, along with PDGF-A and
PDGF-B mRNAs, in several tumor cell lines, but the variable expression patterns
seen in a subset of the cell lines indicates that these genes are differently regulated.
The PDGFs secreted by tumor cells could be responsible for some of the stromal
proliferative or so-called desmoplastic reactions around tumors. Others have
obtained similar results regarding the possible involvement of PDGF-D in tumors,
its expression has been detected from a variety of tumors other than those studied
by us ?LaRochelle et al., 2002?. There has results suggesting involvement of PDGF-
D in prostate cancer, with PDGF-D acting as a potential oncogene ?Ustach et al.,
2004?.
3. Overexpression of PDGF?D induces macrophage accumulation in
normal skin and wound healing and increases the interstitial fluid
pressure ?III?
No obvious differences were detected by macroscopic inspection of the skin of K14-
PDGF-D transgenic mice and their wild type littermates. Epidermal thickness,
dermal cellularity, and blood and lymphatic vessel numbers were similar in
transgenic and wild type skins. Whole mount immunohistochemistry for smooth
muscle actin ?arteries and larger veins? and microlymphangiography using
fluoresecent dextran ?lymphatic vessels? showed no differences between the
transgenic and wild type mice. Instead, large numbers of macrophages accumulated
under the skin of transgenic mice. On average the transgenic mice had 3.7 ± 0.4 fold
more macrophages in the skin than their wild-type littermates. No differences were
found in the numbers of granulocytes or B- and T-lymphocytes in the skin or in the
different leukocyte populations in the peripheral blood, neither was there a
difference in the total number of mononuclear cells or monocytes in the circulation.
Marko Uutela
32
There was no difference in the re-epithelialization of  the skin punch biopsy wounds
between the transgenic and wild type mice. When the number of cells in the
granulation tissue were counted from identical surface areas under the
hyperproliferative epithelium in corresponding areas of the wounds, the cellular
density was in general greater in the K14-PDGF-D positive mice. Total cell influx
into the wound area was greatest in the transgenic mice during the first four days
after wounding, being maximally a 39% increased in the transgenic mice, but the
difference did not reach statistical significance during the later stages of wound
healing.
 The most significant difference between the wounds of the transgenic and wild
type mice was the number of macrophages. During the first four days after
wounding, there was no difference in macrophage influx, but between days five and
seven the macrophage numbers started to decrease in the granulation tissue of wild
type mice, while they continued to increase in the transgenic mice. The number of
macrophages peaked on day seven, being about twofold greater in the transgenic
mice, and this difference persisted until day ten. No endogenous PDGF-D mRNA
was found in the wounds by RT-PCR. This is consistent with the recent report that
PDGF-D is not present in platelets ?Fang et al., 2004?. In the wound granulation
tissue there was no difference detected in number of blood- or lymphatic vessels
between the transgenic and wild-type mice.
 We analyzed the effects of acut e overexpression of PDGF -D in adult skin and
muscle. For this analysis, AAV vectors encoding the full-length PDGF-D ?DFL? or
the activated form ??N? lacking the CUB domain were generated and first tested in
vitro. AAV vectors encoding PDGF-B and HSA were used as controls.
 No difference in blood vessel numbers or the amount of c onnective tissue could be
detected in the injected region. However, when the viruses were injected into mice
transplanted with GFP-marked bone marrow cells from a donor of the same mouse
strain, a strong accumulation of GFP positive cells was detected in the ears injected
with AAV-PDGF-DFL or AAV-PDGF-D?N and a weaker accumulation in the ears
injected with AAV-PDGF-B. Such an accumulation did not take place in ears
injected with AAV encoding HSA or with PBS alone. Immunohistochemical analysis
indicated the presence of numerous macrophages in the AAV-PDGF-D or AAV-
PDGF-D?N injected muscle, but much less in AAV-PDGF-B or AAV-HSA injected
muscles.
PDGF-B has been shown to raise dermal IFP to a normal level after it has been
lowered for example by anaphylaxis ?Rodt et al., 1996?. The inhibition of the
PDGFR-? signaling lowers interstitial hypertension in tumors ?Pietras et al., 2001?,
and increases the efficacy of chemotherapy ?Salnikov et al., 2003?. In the K-14-
PDGF-D mice the IFP measured from the dermis was between -1.0 and -1.5 ?±
0.136? in transgenic mice and -1.1 and -2.1 mmHg ?± 0.065? in wild type mice. This
increase in skin IFP of the transgenic mice was statistically significant.
Our results show that enforced PDGF-D expression in skin increases macrophage
recruitment into the unperturbed skin, and that this effect was enhanced during the
wound healing process. We also observed extensive macrophage accumulation in
skeletal muscle injected with AAV-PDGF-D, whereas much less accumulation was
observed in AAV-PDGF-B injected muscle. These results are consistent with
studies showing that PDGF-B induces macrophage migration via the PDGFR-?
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receptor ?Siegbahn et al., 1990?, although PDGF-D seems to be a more potent
chemoattractant for these cells.
Macrophages are known to play an important role in wound healing by producing a
variety of growth factors and cytokines and by phagocytosing cellular and matrix
debris ?Rappolee et al., 1988?. PDGF purified from platelets accelerates wound
healing by stimulating the chemotaxis and proliferation of fibroblasts, smooth
muscle cells, neutrophils and macrophages ?Pierce et al., 1991?. These effects are
mediated via the activation of PDGFR-?, which is upregulated in connective tissue
cells and epithelial cells during the repair process, explaining the higher
accumulation of cells to wounded areas of the transgenic mice ?Antoniades et al.,
1991; Reuterdahl et al., 1993?. In addition to smooth muscle cells and macrophages
also fibroblasts, which form a major part of the granulation tissue, express PDGFR-
? ?Heldin and Westermark, 1999?. The recombinant soluble PDGF-D could provide
another tool to modulate wound healing via this receptor.
IFP affects capillary fluid filtration and the filling of lymphatic vessels. Many solid
tumors demonstrate interstitial hypertension, thus making the delivery of many
anticancer drugs more difficult. Our results are consistent with the fact that
PDGFR-?  is essential for the maintenance of steady-state IFP ?Wiig, 1990?. Many
solid tumors demonstrate interstitial hypertension, thus making the delivery of
many anticancer drugs more difficult. Our results are consistent with the fact that
PDGFR-? is essential for the maintenance of steady-state IFP ?Pietras et al., 2001?.
Together with earlier results, these define the role of the PDGFR-?  and its ligands
in maintaining and controlling IFP.
4. PDGF?D in blood vessel maturation during angiogenesis ?III?
To investigate the contribution of PDGF-D to vessel stabilization, we tested AAV-
PDGF-D in combination with AAV producing the angiogenic endothelial mitogen
VEGF-E. We observed that AAV-VEGF-E induced a strong angiogenic response
and that the AAV-VEGF-E infected ears had enlarged vessels. SMA stained vessels
showed a loose, irregular coating by smooth muscle cells ?arrows in Figure 7? in
comparison to AAV-HSA infected ears. Ears injected with a combination of AAV-
PDGF-D and AAV-VEGF-E displayed the normal tight structure of the smooth
muscle layer, this is similar to when AAV-PDGF-B was used with AAV-VEGF-E.
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AAV-PDGF-D + AAV-VEGF-EAAV-VEGF-E
Figure 7. Whole mount staining for SMA of AAV?infected ears. The
arteries from AAV-VEGF-E infected ears show an irregular coating by SMCs.
When AAV-PDGF-D is included the vessels appear normal, a tight SMC layer
structure.
In mouse gastrocnemius muscle infected with AAV-VEGF-E alone the vessels were
enlarged, and,  compared to the vasculature of the untreated mice, the SMC coating
was irregular. When AAV-VEGF-E was administered in combination with AAV-
PDGF-D or with AAV-PDGF-B, the vessels were still enlarged but the SMC
coating was thick and regular.
When tested for vascular leakiness by injecting FITC-Dextran into the tail vein, the
vessels in the ears treated with the combination of AAV-PDGF-D or AAV-PDGF-
B and AAV-VEGF-E had reduced leakiness in comparison to the vessels formed in
the ears injected with AAV-VEGF-E alone. By contrast, a VEGF-E induced
increase in blood capillaries was unaffected by AAV-PDGF-D or AAV-PDGF-B,
which, when used alone, did not appear to have any effect on the smooth muscle cell
coating or permeability of the vessels.
There has been a recent report on the angiogenic potential of PDGF-D ?Li et al.,
2003?. In our experiments PDGF-D alone was not angiogenic in the ear or skeletal
muscle, but when expressed together with VEGF-E, which can induce a strong
angiogenic response, it promoted stabilization of the newly generated, enlarged and
leaky vessels induced by VEGF-E alone. This effect may be due to the PDGF-D
induced stimulation of the proliferation and migration of SMCs, which we have
shown for coronary artery SMCs in vitro ?II?. Since our results indicate that PDGF-
D has a significant ability to regulate macrophage recruitment, and that both
PDGF-D and PDGF-B improve the SMC coating of angiogenic blood vessels and
decrease their permeability, it follows that PDGF-D may prove useful in the
development of therapeutic tools for the treatment of wounds and for blood vessel
stabilization in tissue engineering and various proangiogenic therapies to counteract
tissue ischemia.
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CONCLUDING REMARKS
Angiogenesis and the molecules involved in it have been under investigation for
many years now. Over the years several published results have shown how
significantly angiogenesis and angiogenetic factors are involved in tumorigenesis and
vascular diseases. It was therefore particularly interesting to discover a new member
of the growth factor family that has a central role in this field.
 Our first results confirmed that PDGF-D is a close relative of the other members
of the PDGF/VEGF family of growth factors, and we were able to analyse the
structure and organization of the PDGFD  gene and its receptor activation
capability, and, after later results somewhat completed the picture, we were really
able to start exploring its function in vivo, and any possible uses in proangiogenic
therapies.
Our results indicate that mature PDGF-D has similar receptor binding properties as
PDGF-B and that the major difference between the two growth factors is the CUB
domain and its possible role in controlling the cleavage of PDGF-D. We were also
able to clarify the role and significance of the CUB domain in PDGF-D and its
closest relative, PDGF-C. The removal of the CUB domain is necessary for PDGF-
D to become active, and we showed that its removal process controls how much
active PDGF-D there is available.
Considering the major role of macrophages in the formation of atherosclerotic
lesions, and the ability of PDGF-D to recruit them, it would be very interesting to
investigate the role of PDGF-D in the formation of these lesions and atherosclerosis
in general, to see if the blocking of PDGF-D possibly have any therapeutic effect.
This study gives first answers of the involvement of PDGF-D in some pathological
conditions, such as wound healing process, and possible future usage as part of some
therapies such as wound healing, growing of new, functional, blood vessels or
chemotherapy.
Marko Uutela
36
ACKNOWLEDGEMENTS
These studies were made at the Molecular /Cancer Biology Laboratory during May
1998- December 2004. I wish to express my gratitude to my supervisor, Professor
Kari Alitalo, for guiding me trough my research work and always providing
interesting ideas and of course for providing fantastic facilities to work.
I wish to express my deep gratitude for their valuable comments, to the reviewers of
my thesis, Docent Karl Lemstr?m and Docent Olli Ritvos.
Molecular/Cancer Biology Laboratory has been and is filled with bright young
minds, creating a working enviroment which is both intellectually challenging and a
fun place to be. I thank you all. very warmly :-?.
I also want to thank my closest collaborators; Ulf Eriksson, Xuri Li, and Erika
Bergsten from Ludwig institute for cancer research in Stockholm.
Alun Parsons is thanked for making sure the language of the thesis is as close to
good english as possible, and of course for being a good friend for years, in the lab
and outside it. Ddiolch, Alun.
I want to thank Marja Lohela for being a great support for me in the lab and a really
good and close friend outside it. I am deeply grateful to Maria Wirzenius for her
friendship and caring, which have been really important to me especially during the
past year. Warm thanks to Anne Saaristo, who has been my friend and colleague for
six years, and who has always had time to listen my worries. I want also thank
Marika, Lotta, Terhi, Jaana, Iiro, Camilla, Paula and Miia, for unbelievable time in-
and outside the lab, and also for creating a very special kind of atmosphere into our
end of the lab, especially on friday afternoons....And special thaks to Cam for
helping me with my TOC!
Big thanks to Tapio Tainola..He helped me to settle into the lab, has been a good
and solid friend and is the man who knows where everything is.
I want to thank Sanna, Mari, Pipsa, Paula, Riikka and other technicians who have
worked in the lab during my years there and helped me with their great skills!
Among my friends outside the lab world ?amazingly, there still are some...:-??, I must
acknowledge the impact of two of them, Kaisa and Jussi, who have both in their
own way supported me trough these years. Talks with Kaisa have helped me trough
a lot of crises, both in- and outside the work. And Jussi, we have been best friends
for 29 years now ?!!!? and in many ways you are more a brother than a friend to me.
Except that you have been somehow misguided with your choice of the team to
support...
I would like to thank warmly my good, good friend Erja, who has seen more of my
life than anyone during these years, and is one of the closest and most important
persons ever in my life.
Vanhempani, Mirja and V?in? ja edesmennyt iso?itini Elsa ovat tukeneet minua
kaikessa mihin olen el?m?ni aikana ryhtynyt ja haluan ilmaista kiitollisuuteni ja
 PDGF-D, a novel member of the PDGF family
37
rakkauteni heit? kohtaan. Isot kiitokset my?s rakkaalle sisarelleni Anne-Marille
sek? h?nen valitulleen, Arille.
Radio Helsinki was founded in february 2001 and since that day I have listened it
every day at my lab bench and it has created an enjoyable sound enviroment around
my bench, although there might be some persons in the lab who think otherwise :-?.
I am very grateful to following foundations and institutions that have supported my
work financially: The Ida Montin Foundation, Finnish Cancer Organizations, The
Maud Kuistila Memorial Foundation, Biomedicum Helsinki Foundation, Paulo
Foundation, The Finnish- Norwegian Foundation for Medical Research and The
Research and Science Foundation of Farmos.
Marko Uutela
38
REFERENCES
Abe, J., J. Deguchi, T. Matsumoto, N. Takuwa, M. Noda, M. Ohno, M. Makuuchi,
K. Kurokawa, and Y. Takuwa. 1997. Stimulated activation of platelet-derived
growth factor receptor in vivo in balloon-injured arteries: a link between
angiotensin II and intimal thickening. Circulation. 96:1906-13.
Achen, M.G., M. Jeltsch, E. Kukk, T. Makinen, A. Vitali, A.F. Wilks, K. Alitalo,
and S.A. Stacker. 1998. Vascular endothelial growth factor D ?VEGF-D? is a
ligand for the tyrosine kinases VEGF receptor 2 ?Flk1? and VEGF receptor 3
?Flt4?. Proc. Natl Acad. Sci. USA. 95:548-553.
Allt, G., and J.G. Lawrenson. 2001. Pericytes: cell biology and pathology. Cells Tissues
Organs. 169:1-11.
Alon, T., I. Hemo, A. Itin, J. Pe?er, J. Stone, and E. Keshet. 1995. Vascular
endothelial growth factor acts as a survival factor for newly formed retinal
vessels and has implications for retinopathy of prematurity. Nature Med.
1:1024-1028.
Antoniades, H., T. Galanopoulos, J. Neville-Golden, C. Kiritsy, and L. SE. 1991.
Injury induces in vivo expression of platelet-derived growth factor ?PDGF?
and PDGF receptor mRNAs in skin epithelial cells and PDGF mRNA in
connective tissue fibroblasts. Proc Natl Acad Sci U S A. 88:565-9.
Antoniades, H.N., C.D. Scher, and C.D. Stiles. 1979. Purification of human platelet-
derived growth factor. Proc Natl Acad Sci U S A. 76:1809-13.
Arap, W., R. Pasqualini, and E. Ruoslahti. 1998. Cancer treatment by targeted drug
delivery to tumor vasculature in a mouse model. Science. 279:377-80.
Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B.
Witzenbichler, G. Schatteman, and J.M. Isner. 1997. Isolation of putative
progenitor endothelial cells for angiogenesis. Science. 275:964-967.
Bar, R.S., M. Boes, B.A. Booth, B.L. Dake, S. Henley, and M.N. Hart. 1989. The
effects of platelet-derived growth factor in cultured microvessel endothelial
cells. Endocrinology. 124:1841-8.
Barleon, B., S. Hauser, C. Schollmann, K. Weindel, D. Marme, A. Yayon, and H.A.
Weich. 1994. Differential expression of the two VEGF receptors flt and
KDR in placenta and vascular endothelial cells. J Cell Biochem. 54:56-66.
Barrett, T.B., and E.P. Benditt. 1987. sis ?platelet-derived growth factor B chain?
gene transcript levels are elevated in human atherosclerotic lesions compared
to normal artery. Proc Natl Acad Sci U S A. 84:1099-103.
Benjamin, L.E., D. Golijanin, A. Itin, D. Pode, and E. Keshet. 1999. Selective
ablation of immature blood vessels in established human tumors follows
vascular endothelial growth factor withdrawal. J Clin Invest. 103:159-65.
Betsholtz, C. 2004. Insight into the physiological functions of PDGF through
genetic studies in mice. Cytokine Growth Factor Rev. 15:215-28.
Betsholtz, C.,Johnsson A, Heldin CH, Westermark B, Lind P, Urdea MS, Eddy R,
Shows TB, Philpott K and A.L. Mellor. 1986. cDNA sequence and
chromosomal localization of human platelet-derived growth factor A-chain
and its expression in tumour cell lines. Nature. 320:695-699.
Betsholtz, C., and E.W. Raines. 1997. Platelet-derived growth factor: a key regulator
of connective tissue cells in embryogenesis and pathogenesis. Kidney Int.
51:1361-9.
 PDGF-D, a novel member of the PDGF family
39
Bishayee, S., S. Majumdar, J. Khire, and M. Das. 1989. Ligand-induced dimerization
of the platelet-derived growth factor receptor. Monomer-dimer
interconversion occurs independent of receptor phosphorylation. J Biol
Chem. 264:11699-705.
Bonthron, D.T., C.C. Morton, S.H. Orkin, and T. Collins. 1988. Platelet-derived
growth factor A chain: gene structure, chromosomal location, and basis for
alternative mRNA splicing. Proc Natl Acad Sci U S A. 85:1492-6.
Boring, L., J. Gosling, M. Cleary, and I.F. Charo. 1998. Decreased lesion formation
in CCR2-/- mice reveals a role for chemokines in the initiation of
atherosclerosis. Nature. 394:894-7.
Bork, P. 1991. Complement components C1r/C1s, bone morphogenic protein 1 and
Xenopus laevis developmentally regulated protein UVS.2 share common
repeats. FEBS Lett. 282:9-12.
Bostr?m, H., K. Willets, M.Pekny, P.Lev?en, P.Lindahl, H.Hedstrand, M.Pekna,
M.Hellstr?m, S.Gebre-Medhin, M.Scalling, M.Nilsson, S.Kurland, J.T?rnell,
J.K.Heath and C. Betsholtz. 1996. PDGF-A signalling is a critical event in
lung alveolar myofibroblast development and alveogenesis. Cell. 85:863-873.
Broxmeyer, H.E., S. Cooper, Z.H. Li, L. Lu, H.Y. Song, B.S. Kwon, R.E. Warren,
and D.B. Donner. 1995. Myeloid progenitor cell regulatory effects of vascular
endothelial cell growth factor. Int J Hematol. 62:203-15.
Cao, R., E. Brakenhielm, X. Li, K. Pietras, J. Widenfalk, A. Ostman, U. Eriksson,
and Y. Cao. 2002. Angiogenesis stimulated by PDGF-CC, a novel member in
the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta
receptors. Faseb J. 16:1575-83.
Cao, R., E. Brakenhielm, R. Pawliuk, D. Wariaro, M.J. Post, E. Wahlberg, P.
Leboulch, and Y. Cao. 2003. Angiogenic synergism, vascular stability and
improvement of hind-limb ischemia by a combination of PDGF-BB and
FGF-2. Nat Med. 9:604-13.
Cao, Y., W.R. Ji, P. Qi, A. Rosin, and Y. Cao. 1997. Placenta growth factor:
identification and characterization of a novel isoform generated by RNA
alternative splicing. Biochemical & Biophysical Research Communications. 235:493-
8.
Carmeliet, P., and D. Collen. 2000. Transgenic mouse models in angiogenesis and
cardiovascular disease. J Pathol. 190:387-405.
Claesson-Welsh, L., Hammacher, A., Westermark, B., Heldin, C.-H., and M.
Nister. 1989. Identification and structural analysis of the A type receptor for
platelet derived growth factor. J. Biol. Chem.:1742-1747.
Clauss, M., M. Gerlach, H. Gerlach, J. Brett, F. Wang, P.C. Familetti, Y.-C.E. Pan,
J.V. Olander, D.T. Connolly, and D. Stern. 1990. Vascular permeability
factor: a tumor-derived polypeptide that induces endothelial cell and
monocyte procoagulant activity and promotes monocyte migration. J. Exp.
Med. 172:1535-1545.
Clauss, M., H. Weich, G. Breier, U. Knies, W. Rockl, J. Waltenberger, and W.
Risau. 1996. The vascular endothelial growth factor receptor Flt-1 mediates
biological activities. Implications for a functional role of placenta growth
factor in monocyte activation and chemotaxis. J Biol Chem. 271:17629-34.
Collins, T., J.S. Pober, M.A. Gimbrone, Jr., A. Hammacher, C. Betsholtz, B.
Westermark, and C.H. Heldin. 1987. Cultured human endothelial cells
express platelet-derived growth factor A chain. Am J Pathol. 126:7-12.
Connolly, D.T., D.M. Heuvelman, R. Nelson, J.V. Olander, and B.L. Eppley. 1989.
Tumor vascular permeability factor stimulates endothelial cell growth and
angiogenesis. J. Clin. Invest. 84:1478-1489.
Marko Uutela
40
Conway, E.M., and P. Carmeliet. 2004. The diversity of endothelial cells: a
challenge for therapeutic angiogenesis. Genome Biol. 5:207.
Cottone, R., M. Buttner, B. Bauer, M. Henkel, E. Hettich, and H.J. Rziha. 1998.
Analysis of genomic rearrangement and subsequent gene deletion of the
attenuated Orf virus strain D1701. Virus Res. 56:53-67.
Coussens, L., C. Van Beveren, D. Smith, E. Chen, R. Mitchell, C. Isacke, I. Verma,
and A. Ullrich. 1986. Structural alteration of viral homologue of receptor
proto-oncogene fms at carboxyl terminus. Nature. 320:277-280.
Dalla-Favera, R., R.C. Gallo, A. Giallongo, and C.M. Croce. 1982. Chromosomal
localization of the human homolog ?c-sis? of the simian sarcoma virus onc
gene. Science. 218:686-8.
DiSalvo, J., M.L. Bayne, G. Conn, P.W. Kwok, P.G. Trivedi, D.D. Soderman, T.M.
Palisi, K.A. Sullivan, and K.A. Thomas. 1995. Purification and
characterization of a naturally occurring vascular endothelial growth
factor.placenta growth factor heterodimer. Journal of Biological Chemistry.
270:7717-23.
Doolittle, R.F., M.W. Hunkapiller, L.E. Hood, S.G. Devare, K.C. Robbins, S.A.
Aaronson, and H.N. Antoniades. 1983. Simian sarcoma virus onc gene, v-sis,
is derived from the gene ?or genes? encoding a platelet-derived growth factor.
Science. 221:275-7.
Dor, Y., V. Djonov, R. Abramovitch, A. Itin, G.I. Fishman, P. Carmeliet, G.
Goelman, and E. Keshet. 2002. Conditional switching of VEGF provides
new insights into adult neovascularization and pro-angiogenic therapy. Embo
J. 21:1939-47.
Dvorak, H.F., L.F. Brown, M. Detmar, and A.M. Dvorak. 1995. Vascular
permeability factor/vascular endothelial growth factor, microvascular
hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029-1039.
Eriksson, A., A. Siegbahn, B. Westermark, C.H. Heldin, and L. Claesson-Welsh.
1992. PDGF alpha- and beta-receptors activate unique and common signal
transduction pathways. Embo J. 11:543-50.
Evanko, S.P., E.W. Raines, R. Ross, L.I. Gold, and T.N. Wight. 1998. Proteoglycan
distribution in lesions of atherosclerosis depends on lesion severity,
structural characteristics, and the proximity of platelet-derived growth factor
and transforming growth factor-beta. Am J Pathol. 152:533-46.
Fang, L., Y. Yan, L.G. Komuves, S. Yonkovich, C.M. Sullivan, B. Stringer, S.
Galbraith, N.A. Lokker, S.S. Hwang, P. Nurden, D.R. Phillips, and N.A.
Giese. 2004. PDGF C is a selective alpha platelet-derived growth factor
receptor agonist that is highly expressed in platelet alpha granules and
vascular smooth muscle. Arterioscler Thromb Vasc Biol. 24:787-92.
Ferns, G.A., E.W. Raines, K.H. Sprugel, A.S. Motani, M.A. Reidy, and R. Ross.
1991. Inhibition of neointimal smooth muscle accumulation after angioplasty
by an antibody to PDGF. Science. 253:1129-32.
Ferrara, N., and T. Davis-Smyth. 1997. The biology of vascular endothelial growth
factor. Endocrine Reviews. 18:4-25.
Ferrara, N., H.P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its
receptors. Nat Med. 9:669-76.
Ferrara, N., and W.J. Henzel. 1989. Pituitary follicular cells secrete a novel heparin-
binding growth factor specific for vascular endothelial cells. Biochem. Biophys.
Res. Commun. 161:851-855.
Floege, J., K.L. Hudkins, C.L. Davis, S.M. Schwartz, and C.E. Alpers. 1998.
Expression of PDGF alpha-receptor in renal arteriosclerosis and rejecting
renal transplants. J Am Soc Nephrol. 9:211-23.
 PDGF-D, a novel member of the PDGF family
41
Fong, G.-H., L. Zhang, D.-M. Bryce, and J. Peng. 1999. Increased hemangioblast
commitment, not vascular disorganization, is the primary defect in flt-1
knock-out mice. Development. 126:3015-3025.
Fredriksson, L., H. Li, and U. Eriksson. 2004. The PDGF family: four gene
products form five dimeric isoforms. Cytokine Growth Factor Rev. 15:197-204.
Fruttiger, M., et al. 1999. Defective oligodendrocyte development and severe
hypomyelination in PDGF-A knockout mice. Development. 126:457-467.
Gee, M.S., W.N. Procopio, S. Makonnen, M.D. Feldman, N.M. Yeilding, and
W.M. Lee. 2003. Tumor vessel development and maturation impose limits
on the effectiveness of anti-vascular therapy. Am J Pathol. 162:183-93.
Gerber, H.P., A. McMurtrey, J. Kowalski, M. Yan, B.A. Keyt, V. Dixit, and N.
Ferrara. 1998. Vascular endothelial growth factor regulates endothelial cell
survival through the phosphatidylinositol 3?-kinase/Akt signal transduction
pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:30336-
30343.
Giese, N.A., M.M. Marijianowski, O. McCook, A. Hancock, V. Ramakrishnan, L.J.
Fretto, C. Chen, A.B. Kelly, J.A. Koziol, J.N. Wilcox, and S.R. Hanson.
1999. The role of alpha and beta platelet-derived growth factor receptor in
the vascular response to injury in nonhuman primates. Arterioscler Thromb
Vasc Biol. 19:900-9.
Gilbertson, D.G., M.E. Duff, J.W. West, J.D. Kelly, P.O. Sheppard, P.D.
Hofstrand, Z. Gao, K. Shoemaker, T.R. Bukowski, M. Moore, A.L. Feldhaus,
J.M. Humes, T.E. Palmer, and C.E. Hart. 2001. Platelet-derived growth
factor C ?PDGF-C?, a novel growth factor that binds to PDGF alpha and
beta receptor. J Biol Chem. 276:27406-14.
Gille, H., J. Kowalski, B. Li, J. LeCouter, B. Moffat, T.F. Zioncheck, N. Pelletier,
and N. Ferrara. 2001. Analysis of biological effects and signaling properties of
Flt-1 ?VEGFR-1? and KDR ?VEGFR-2?. A reassessment using novel
receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem.
276:3222-3230.
Haniu, M., P. Hsieh, M.F. Rohde, and W.C. Kenney. 1994. Characterization of
disulfide linkages in platelet-derived growth factor AA. Arch Biochem Biophys.
310:433-7.
Haniu, M., M.F. Rohde, and W.C. Kenney. 1993. Disulfide bonds in recombinant
human platelet-derived growth factor BB dimer: characterization of
intermolecular and intramolecular disulfide linkages. Biochemistry. 32:2431-7.
Hart, I.K., W.D. Richardson, C.H. Heldin, B. Westermark, and M.C. Raff. 1989.
PDGF receptors on cells of the oligodendrocyte-type-2 astrocyte ?O-2A? cell
lineage. Development. 105:595-603.
Hashizume, H., Baluk, P., Morikawa S., McLean, J.W., Thurston, G., Roberge, S.,
Jain, R., McDonald, D.M. 2000. Openings between defective endothelial
cells explain tumor vessel leakiness. Am. J. Pathol. 156:1363-1380.
Hattori, K., B. Heissig, Y. Wu, S. Dias, R. Tejada, B. Ferris, D.J. Hicklin, Z. Zhu, P.
Bohlen, L. Witte, J. Hendrikx, N.R. Hackett, R.G. Crystal, M.A. Moore, Z.
Werb, D. Lyden, and S. Rafii. 2002. Placental growth factor reconstitutes
hematopoiesis by recruiting VEGFR1?+? stem cells from bone-marrow
microenvironment. Nat Med. 8:841-9.
Heidaran, M., J. Pierce, R. Jensen, T. Matsui, and S. Aaronson. 1990. Chimeric a-
and b-platelet derived growth factor ?PDGF? receptors define three
immunoglobulin-like domains of the a-PDGF receptor that determine
PDGF-AA binding specificity. 265:18741-18744.
Heldin, C.-H., and B. Westermark. 1996. Role of Platelet-Derived Growth Factor in
vivo. R.A.F. Clark, editor. Plenum, New York. 249-273.
Marko Uutela
42
Heldin, C.-H., and B. Westermark. 1999. Mechanism of Action and in vivo role of
platelet derived growth factor. Physiologigal reviews. 79:1283 - 1316.
Heldin, C.-H., B. Westermark, and ?. Wasteson. 1979. Platelet-derived growth
factor: purification and partial characterization. Proc. Natl. Acad. Sci. 76:3722-
3726.
Heldin, C.H., A. Ernlund, C. Rorsman, and L. Ronnstrand. 1989. Dimerization of B-
type platelet-derived growth factor receptors occurs after ligand binding and
is closely associated with receptor kinase activation. J Biol Chem. 264:8905-12.
Heldin, P., H. Pertoft, H. Nordlinder, C.H. Heldin, and T.C. Laurent. 1991.
Differential expression of platelet-derived growth factor alpha- and beta-
receptors on fat-storing cells and endothelial cells of rat liver. Exp Cell Res.
193:364-9.
Hellstrom, M., H. Gerhardt, M. Kalen, X. Li, U. Eriksson, H. Wolburg, and C.
Betsholtz. 2001. Lack of pericytes leads to endothelial hyperplasia and
abnormal vascular morphogenesis. J. Cell Biol. 153:543-553.
Hellstrom, M., M. Kalen, P. Lindahl, A. Abramsson, and C. Betsholtz. 1999. Role of
PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells
and pericytes during embryonic blood vessel formation in the mouse.
Development. 126:3047-55.
Hermanson, M., K. Funa, M. Hartman, L. Claesson-Welsh, C.H. Heldin, B.
Westermark, and M. Nister. 1992. Platelet-derived growth factor and its
receptors in human glioma tissue: expression of messenger RNA and protein
suggests the presence of autocrine and paracrine loops. Cancer Res. 52:3213-9.
Hermanson, M., K. Funa, J. Koopmann, D. Maintz, A. Waha, B. Westermark, C.H.
Heldin, O.D. Wiestler, D.N. Louis, A. von Deimling, and M. Nister. 1996.
Association of loss of heterozygosity on chromosome 17p with high platelet-
derived growth factor alpha receptor expression in human malignant gliomas.
Cancer Res. 56:164-71.
Hosang, M., M. Rouge, B. Wipf, B. Eggimann, F. Kaufmann, and W. Hunziker.
1989. Both homodimeric isoforms of PDGF ?AA and BB? have mitogenic and
chemotactic activity and stimulate phosphoinositol turnover. J Cell Physiol.
140:558-64.
Hughes, D.C. 2001. Alternative splicing of the human VEGFGR-3/FLT4 gene as a
consequence of an integrated human endogenous retrovirus. J. Mol. Evol.
53:77-79.
Hungerford, J.E., and C.D. Little. 1999. Developmental biology of the vascular
smooth muscle cell: building a multilayered vessel wall. J Vasc Res. 36:2-27.
Jawien, A., D.F. Bowen-Pope, V. Lindner, S.M. Schwartz, and A.W. Clowes. 1992.
Platelet-derived growth factor promotes smooth muscle migration and
intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 89:507-
11.
Jeltsch, M., A. Kaipainen, V. Joukov, X. Meng, M. Lakso, H. Rauvala, M. Swartz, D.
Fukumura, R.K. Jain, and K. Alitalo. 1997. Hyperplasia of lymphatic vessels
in VEGF-C transgenic mice. Science. 276:1423-1425.
Johnsson, A., C.H. Heldin, A. Wasteson, B. Westermark, T.F. Deuel, J.S. Huang,
P.H. Seeburg, A. Gray, A. Ullrich, G. Scrace, and et al. 1984. The c-sis gene
encodes a precursor of the B chain of platelet-derived growth factor. Embo J.
3:921-8.
Joukov, V., K. Pajusola, A. Kaipainen, D. Chilov, I. Lahtinen, E. Kukk, O. Saksela,
N. Kalkkinen, and K. Alitalo. 1996. A novel vascular endothelial growth
factor, VEGF-C, is a ligand for the Flt4 ?VEGFR-3? and KDR ?VEGFR-2?
receptor tyrosine kinases. EMBO J. 15:290-298.
 PDGF-D, a novel member of the PDGF family
43
Joukov, V., T. Sorsa, V. Kumar, M. Jeltsch, L. Claesson-Welsh, Y. Cao, O. Saksela,
N. Kalkkinen, and K. Alitalo. 1997. Proteolytic processing regulates receptor
specificity and activity of VEGF-C. EMBO J. 16:3898-3911.
Kaipainen, A., J. Korhonen, T. Mustonen, V.W.M. van Hinsbergh, G.-H. Fang, D.
Dumont, M. Breitman, and K. Alitalo. 1995. Expression of the fms-like
tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium
during development. Proc. Natl Acad. Sci. USA. 92:3566-3570.
Kaplan, D.R., F.C. Chao, C.D. Stiles, H.N. Antoniades, and C.D. Scher. 1979.
Platelet alpha granules contain a growth factor for fibroblasts. Blood. 53:1043-
52.
Karkkainen, M.J., A. Saaristo, L. Jussila, K.A. Karila, E.C. Lawrence, K. Pajusola, H.
Bueler, A. Eichmann, R. Kauppinen, M.I. Kettunen, S. Yl?-Herttuala, D.N.
Finegold, R.E. Ferrell, and K. Alitalo. 2001. A model for gene therapy of
human hereditary lymphedema. Proc. Natl Acad. Sci. USA. 98:12677-12682.
Karlsson, L., P. Lindahl, J.K. Heath, and C. Betsholtz. 2000. Abnormal
gastrointestinal development in PDGF-A and PDGFR-?alpha? deficient mice
implicates a novel mesenchymal structure with putative instructive
properties in villus morphogenesis. Development. 127:3457-66.
Katano, M., M. Nakamura, K. Fujimoto, K. Miyazaki, and T. Morisaki. 1998.
Prognostic value of platelet-derived growth factor-A ?PDGF-A? in gastric
carcinoma. Ann Surg. 227:365-71.
Katoh, O., H. Tauchi, K. Kawaishi, A. Kimura, and Y. Satow. 1995. Expression of
the vascular endothelial growth factor ?VEGF? receptor gene, KDR, in
hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death
caused by ionizing radiation. Cancer Res. 55:5687-92.
Kendall, R.L., and K.A. Thomas. 1993. Inhibition of vascular endothelial cell growth
factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad.
Sci. USA. 90:10705-10709.
Keyt, B.A., H.V. Nguyen, L.T. Berleau, C.M. Duarte, J. Park, H. Chen, and N.
Ferrara. 1996. Identification of vascular endothelial growth factor
determinants for binding KDR and FLT-1 receptors. Generation of receptor-
selective VEGF variants by site-directed mutagenesis. J. Biol. Chem. 271:5638-
5646.
Kiba, A., H. Sagara, T. Hara, and M. Shibuya. 2003. VEGFR-2-specific ligand
VEGF-E induces non-edematous hyper-vascularization in mice. Biochem
Biophys Res Commun. 301:371-7.
Kohler, N., and A. Lipton. 1974. Platelets as a source of fibroblast growth-
promoting activity. Exp Cell Res. 87:297-301.
Koyama, H., Y. Nishizawa, M. Hosoi, S. Fukumoto, K. Kogawa, A. Shioi, and H.
Morii. 1996. The fumagillin analogue TNP-470 inhibits DNA synthesis of
vascular smooth muscle cells stimulated by platelet-derived growth factor and
insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase
2. Circ Res. 79:757-64.
Landgren, E., P. Schiller, Y. Cao, and L. Claesson-Welsh. 1998. Placenta growth
factor stimulates MAP kinase and mitogenicity but not phospholipase C-
gamma and migration of endothelial cells expressing Flt 1. Oncogene. 16:359-
67.
LaRochelle, W.J., M. Jeffers, J.R. Corvalan, X.C. Jia, X. Feng, S. Vanegas, J.D.
Vickroy, X.D. Yang, F. Chen, G. Gazit, J. Mayotte, J. Macaluso, B. Rittman,
F. Wu, M. Dhanabal, J. Herrmann, and H.S. Lichenstein. 2002. Platelet-
derived growth factor D: tumorigenicity in mice and dysregulated expression
in human cancer. Cancer Res. 62:2468-73.
Marko Uutela
44
LaRochelle, W.J., M. Jeffers, W.F. McDonald, R.A. Chillakuru, N.A. Giese, N.A.
Lokker, C. Sullivan, F.L. Boldog, M. Yang, C. Vernet, C.E. Burgess, E.
Fernandes, L.L. Deegler, B. Rittman, J. Shimkets, R.A. Shimkets, J.M.
Rothberg, and H.S. Lichenstein. 2001. PDGF-D, a new protease-activated
growth factor. Nat. Cell Biol. 3:517-521.
Leppanen, O., Janjic, N., Carlsson, MA., Pietras, K., Levin, M. ,Vargeese, C., Green,
LS., Bergqvist, D., Ostman, A., Heldin, CH. 2000. Intimal hyperplasia recurs
after removal of PDGF-AB and ?BB inhibition in the rat carotid artery injury
model. Arteriosclerosis Thrombosis & Vascular Biology. 20:E89-E95.
Leung, D.W., G. Cachianes, W.-J. Kuang, D.V. Goeddel, and N. Ferrara. 1989.
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science.
246:1306-1309.
Lev?en, P.M.P., S.Gebre-Medhin, B.Swolin, E.Larsson and C.Betsholz. 1994. Mice
deficient for PDGF-B show renal, cardiovascular and hematological
abnormalities. Genes Dev. 8:1875-1887.
Li, H., L. Fredriksson, X. Li, and E. U. 2003. PDGF-D is a potent transforming and
angiogenic growth factor. Oncogene. 22:1501-10.
Li, X., A. Ponten, K. Aase, L. Karlsson, A. Abramsson, M. Uutela, G. Backstrom,
M. Hellstrom, H. Bostrom, H. Li, P. Soriano, C. Betsholtz, C.H. Heldin, K.
Alitalo, A. Ostman, and U. Eriksson. 2000. PDGF-C is a new protease-
activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2:302-9.
Li, X.R., and U. Eriksson. 2001. Novel VEGF family members: VEGF-B, VEGF-C
and VEGF-D ?Review?. Int. J. Biochem. Cell Biol. 33:421-426.
Lindahl, P., M. Hellstrom, M. Kalen, L. Karlsson, M. Pekny, M. Pekna, P. Soriano,
and C. Betsholtz. 1998. Paracrine PDGF-B/PDGF-Rbeta signaling controls
mesangial cell development in kidney glomeruli. Development. 125:3313-22.
Lindahl, P., B.R. Johansson, P. Leveen, and C. Betsholtz. 1997a. Pericyte loss and
microaneurysm formation in PDGF-B-deficient mice. Science. 277:242-5.
Lindahl, P., L. Karlsson, M. Hellstrom, S. Gebre-Medhin, K. Willetts, J.K. Heath,
and C. Betsholtz. 1997b. Alveogenesis failure in PDGF-A-deficient mice is
coupled to lack of distal spreading of alveolar smooth muscle cell progenitors
during lung development. Development. 124:3943-53.
Luttun, A., M. Tjwa, L. Moons, Y. Wu, A. Angelillo-Scherrer, F. Liao, J.A. Nagy, A.
Hooper, J. Priller, B. De Klerck, V. Compernolle, E. Daci, P. Bohlen, M.
Dewerchin, J.M. Herbert, R. Fava, P. Matthys, G. Carmeliet, D. Collen, H.F.
Dvorak, D.J. Hicklin, and P. Carmeliet. 2002. Revascularization of ischemic
tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis
and atherosclerosis by anti-Flt1. Nat Med. 8:831-40.
Lyttle, D.J., K.M. Fraser, S.B. Fleming, A.A. Mercer, and A.J. Robinson. 1994.
Homologs of vascular endothelial growth factor are encoded by the poxvirus
orf virus. J Virol. 68:84-92.
Maglione, D., V. Guerriero, G. Viglietto, P. Delli-Bovi, and M.G. Persico. 1991.
Isolation of a human placenta cDNA coding for a protein related to the
vascular permeability factor. Proc. Natl. Acad. Sci. USA. 88:9267-9271.
Maglione, D., V. Guerriero, G. Viglietto, M.G. Ferraro, O. Aprelikova, K. Alitalo,
S. Del Vecchio, K.-J. Lei, J.Y. Chou, and M.G. Persico. 1993. Two alternative
mRNAs coding for the angiogenic factor, placenta growth factor ?PlGF?, are
transcribed from a single gene of chromosome 14. Oncogene. 8:925-931.
Majesky, M.W., E.P. Benditt, and S.M. Schwartz. 1988. Expression and
developmental control of platelet-derived growth factor A-chain and B-
chain/Sis genes in rat aortic smooth muscle cells. Proc Natl Acad Sci U S A.
85:1524-8.
 PDGF-D, a novel member of the PDGF family
45
Makinen, T., T. Veikkola, S. Mustjoki, T. Karpanen, B. Catimel, E.C. Nice, L.
Wise, A. Mercer, H. Kowalski, D. Kerjaschki, S.A. Stacker, M.G. Achen,
and K. Alitalo. 2001. Isolated lymphatic endothelial cells transduce growth,
survival and migratory signals via the VEGF-C/D receptor VEGFR-3. Embo
J. 20:4762-73.
Maresta, A., M. Balducelli, L. Cantini, A. Casari, R. Chioin, M. Fabbri, A.
Fontanelli, P.A. Monici Preti, S. Repetto, S. De Servi, and et al. 1994.
Trapidil ?triazolopyrimidine?, a platelet-derived growth factor antagonist,
reduces restenosis after percutaneous transluminal coronary angioplasty.
Results of the randomized, double-blind STARC study. Studio Trapidil
versus Aspirin nella Restenosi Coronarica. Circulation. 90:2710-5.
Matsui, T., M. Heideran, T. Miki, N. Popescu, W. La Rochelle, M. Kraus, J. Pierce,
and S.A. Aaronson. 1989. Isolation of a novel receptor cDNA establishes the
existence of two PDGF receptor genes. Science. 243:800-803.
Matthews, W., C.T. Jordan, M. Gavin, N.A. Jenkins, N.G. Copeland, and I.R.
Lemischka. 1991. A receptor tyrosine kinase cDNA isolated from a
population of enriched primitive hematopoetic cells and exhibiting close
genetic linkage to c-kit. Proc. Natl Acad. Sci. USA. 88:9026-9030.
Mercer, A.A., L.M. Wise, A. Scagliarini, C.J. McInnes, M. Buttner, H.J. Rziha, C.A.
McCaughan, S.B. Fleming, N. Ueda, and P.F. Nettleton. 2002. Vascular
endothelial growth factors encoded by Orf virus show surprising sequence
variation but have a conserved, functionally relevant structure. J Gen Virol.
83:2845-55.
Meyer, M., M. Clauss, A. Lepple-Wienhues, J. Waltenberger, H.G. Augustin, M.
Ziche, C. Lanz, M. B?ttner, H.-J. Rziha, and C. Dehio. 1999. A novel
vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates
angiogenesis via signaling through VEGFR-2 ?KDR? but not VEGFR-1 ?Flt-
1? receptor tyrosine kinases. EMBO J. 18:363-374.
Nagaoka, I., S. Honma, A. Someya, K. Iwabuchi, and T. Yamashita. 1992.
Differential expression of the platelet-derived growth factor-A and -B genes
during maturation of monocytes to macrophages. Comp Biochem Physiol B.
103:349-56.
Nakamura, M., M. Katano, K. Fujimoto, and T. Morisaki. 1997. A new prognostic
strategy for gastric carcinoma: mRNA expression of tumor growth-related
factors in endoscopic biopsy specimens. Ann Surg. 226:35-42.
Nehls, V., and D. Drenckhahn. 1993. The versatility of microvascular pericytes:
from mesenchyme to smooth muscle? Histochemistry. 99:1-12.
Ni, W., K. Egashira, S. Kitamoto, C. Kataoka, M. Koyanagi, S. Inoue, K. Imaizumi,
C. Akiyama, K.I. Nishida, and A. Takeshita. 2001. New anti-monocyte
chemoattractant protein-1 gene therapy attenuates atherosclerosis in
apolipoprotein E-knockout mice. Circulation. 103:2096-101.
Nicosia, R.F., and S. Villaschi. 1995. Rat aortic smooth muscle cells become
pericytes during angiogenesis in vitro. Lab Invest. 73:658-66.
Nilsson, J., M. Sjolund, L. Palmberg, J. Thyberg, and C.H. Heldin. 1985. Arterial
smooth muscle cells in primary culture produce a platelet-derived growth
factor-like protein. Proc Natl Acad Sci U S A. 82:4418-22.
Noble, M., K. Murray, P. Stroobant, M.D. Waterfield, and P. Riddle. 1988. Platelet-
derived growth factor promotes division and motility and inhibits premature
differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell.
Nature. 333:560-2.
Oh, S.J., M.M. Jeltsch, R. Birkenhager, J.E. McCarthy, H.A. Weich, B. Christ, K.
Alitalo, and J. Wilting. 1997. VEGF and VEGF-C: specific induction of
Marko Uutela
46
angiogenesis and lymphangiogenesis in the differentiated avian
chorioallantoic membrane. Developmental Biology. 188:96-109.
Olofsson, B., M. Jeltsch, U. Eriksson, and K. Alitalo. 1999. Current biology of
VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 10:528-35.
Olofsson, B., E. Korpelainen, M.S. Pepper, S.J. Mandriota, K. Aase, V. Kumar, Y.
Gunji, M.M. Jeltsch, M. Shibuya, K. Alitalo, and U. Eriksson. 1998. Vascular
endothelial growth factor B ?VEGF-B? binds to VEGF receptor-1 and
regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad.
Sci. USA. 95:11709-11714.
Olofsson, B., K. Pajusola, A. Kaipainen, G. von Euler, V. Joukov, O. Saksela, A.
Orpana, R.F. Pettersson, K. Alitalo, and U. Eriksson. 1996. Vascular
endothelial growth factor B, a novel growth factor for endothelial cells. Proc.
Natl Acad. Sci. USA. 93:2576-2581.
Ostman, A., J. Thyberg, B. Westermark, and C.H. Heldin. 1992. PDGF-AA and
PDGF-BB biosynthesis: proprotein processing in the Golgi complex and
lysosomal degradation of PDGF-BB retained intracellularly. J Cell Biol.
118:509-19.
Panek, R.L., T.K. Dahring, B.J. Olszewski, and J.A. Keiser. 1997. PDGF receptor
protein tyrosine kinase expression in the balloon-injured rat carotid artery.
Arterioscler Thromb Vasc Biol. 17:1283-8.
Park, J.E., H.H. Chen, J. Winer, K.A. Houck, and N. Ferrara. 1994. Placenta growth
factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro
and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol.
Chem. 269:25646-25654.
Paulsson, Y., A. Hammacher, C.H. Heldin, and B. Westermark. 1987. Possible
positive autocrine feedback in the prereplicative phase of human fibroblasts.
Nature. 328:715-7.
Pierce, G.F., T.A. Mustoe, B.W. Altrock, T.F. Deuel, and A. Thomason. 1991. Role
of Platelet-Derived Groth Factor in wound healing. J Cell Biochem. 45:319-326.
Pietras, K., A. Ostman, M. Sjoquist, E. Buchdunger, R.K. Reed, C.H. Heldin, and
K. Rubin. 2001. Inhibition of platelet-derived growth factor receptors
reduces interstitial hypertension and increases transcapillary transport in
tumors. Cancer Res. 61:2929-34.
Pietras, K., K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.H. Heldin, and A.
Ostman. 2002. Inhibition of PDGF receptor signaling in tumor stroma
enhances antitumor effect of chemotherapy. Cancer Res. 62:5476-84.
Pipp, F., M. Heil, K. Issbrucker, T. Ziegelhoeffer, S. Martin, J. van den Heuvel, H.
Weich, B. Fernandez, G. Golomb, P. Carmeliet, W. Schaper, and M. Clauss.
2003. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence
for a monocyte-mediated mechanism. Circ Res. 92:378-85.
Plouet, J., J. Schilling, and D. Gospodarowicz. 1989. Isolation and characterization
of a newly identified endothelial cell mitogen produced by AtT-20 cells.
EMBO J. 8:3801-3806.
Raines, E.W., Bowen-Pope, D.F. and Ross, R. 1991. Platelet Derived Growth
Factor. In Peptide Growth Factors and Their Receptors. M.B.a.R. Sporn,
A.B., editor. Springer-Verlag, New York. 173-262.
Rappolee, D.A., D. Mark, M.J. Banda, and Z. Werb. 1988. Wound macrophages
express TGF-alpha and other growth factors in vivo: analysis by mRNA
phenotyping. Science. 241:708-12.
Reuterdahl, C., C. Sundberg, K. Rubin, K. Funa, and G. B. 1993. Tissue localization
of beta receptors for platelet-derived growth factor and platelet-derived
growth factor B chain during wound repair in humans. J Clin Invest. 91:2065-
75.
 PDGF-D, a novel member of the PDGF family
47
Richardson, T.P., M.C. Peters, A.B. Ennett, and D.J. Mooney. 2001. Polymeric
system for dual growth factor delivery. Nat Biotechnol. 19:1029-34.
Richardson, W.D., N. Pringle, M.J. Mosley, B. Westermark, and M. Dubois-Dalcq.
1988. A role for platelet derived growth factor in normal gliogenesis in the
central nervous system. Cell. 53:309-319.
Risau, W. 1997. Mechanisms of angiogenesis. Nature. 386:671-674.
Risau, W., and I. Flamme. 1995. Vasculogenesis. Annu Rev Cell Dev Biol. 11:73-91.
Rodt, S.A., K. Ahlen, A. Berg, K. Rubin, and R.K. Reed. 1996. A novel physiological
function for platelet-derived growth factor-BB in rat dermis. J Physiol.
495:193-200.
Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s.
Nature. 362:801-9.
Ross, R. 1999. Atherosclerosis--an inflammatory disease. N Engl J Med. 340:115-26.
Ross, R., J. Glomset, B. Kariya, and L. Harker. 1974. A platelet-dependent serum
factor that stimulates the proliferation of arterial smooth muscle cells in
vitro. Proc Natl Acad Sci U S A. 71:1207-10.
Ross, R., J. Masuda, E. Raines, A. Gown, S. Katsuda, M. Sasahara, L. Malden, H.
Masuko, and S. H. 1990. Localization of PDGF-B protein in macrophages in
all phases of atherogenesis. Science. 248:1009-12.
Rubin, K., A. Tingstrom, G.K. Hansson, E. Larsson, L. Ronnstrand, L. Klareskog,
L. Claesson-Welsh, C.H. Heldin, B. Fellstrom, and L. Terracio. 1988.
Induction of B-type receptors for platelet-derived growth factor in vascular
inflammation: possible implications for development of vascular proliferative
lesions. Lancet. 1:1353-6.
Saaristo, A., M.J. Karkkainen, and K. Alitalo. 2002. Insights into the molecular
pathogenesis and targeted treatment of lymphedema. Ann N Y Acad Sci.
979:94-110.
Salnikov, A.V., V.V. Iversen, M. Koisti, C. Sundberg, L. Johansson, L.B. Stuhr, M.
Sjoquist, H. Ahlstrom, R.K. Reed, and K. Rubin. 2003. Lowering of tumor
interstitial fluid pressure specifically augments efficacy of chemotherapy.
FASEB J. 17:1756-8.
Salven, P., A. Lymboussaki, P. Heikkila, H. Jaaskela-Saari, B. Enholm, K. Aase, G.
von Euler, U. Eriksson, K. Alitalo, and H. Joensuu. 1998. Vascular
endothelial growth factors VEGF-B and VEGF-C are expressed in human
tumors ?see comments?. Am. J. of Pathology. 153:103-8.
Schollmann, C., R. Grugel, D. Tatje, J. Hoppe, J. Folkman, D. Marme, and H.A.
Weich. 1992. Basic fibroblast growth factor modulates the mitogenic potency
of the platelet-derived growth factor ?PDGF? isoforms by specific
upregulation of the PDGF alpha receptor in vascular smooth muscle cells. J
Biol Chem. 267:18032-9.
Seetharam, L., N. Gotoh, Y. Maru, G. Neufeld, S. Yamaguchi, and M. Shibuya.
1995. A unique signal transduction from FLT tyrosine kinase, a receptor for
vascular endothelial growth factor VEGF. Oncogene. 10:135-147.
Seifert, R.A., Hart, C.E., Pillips, P.E., Forstrom, J.W., Ross, R., Murray, M.J. and
Bowen-Pope, D.F. 1989. Two different subunits associate to create isoform-
specific platelet derived growth factor receptors. J. Biol. Chem:8771-8778.
Senger, D.R., S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak.
1983. Tumor cells secrete a vascular permeability factor that promotes
accumulation of ascites fluid. Science. 219:983-985.
Shibuya, M., S. Yamaguchi, A. Yamane, T. Ikeda, A. Tojo, H. Matsushime, and M.
Sato. 1990. Nucleotide sequence and expression of a novel human receptor
type tyrosine kinase gene ?flt? closely related to the fms family. Oncogene.
5:519-524.
Marko Uutela
48
Shunichi, M., Baluk, P., Kaidoh, T., Haskell, A., Jain, R.K., McDonald, D.M. 2002.
Abnormalities in pericytes on blood vessels and endothelial sprouts in
tumors. Am. J. Pathol. 160:985-1000.
Shure, D., R.M. Senior, G.L. Griffin, and T.F. Deuel. 1992. PDGF AA homodimers
are potent chemoattractants for fibroblasts and neutrophils, and for
monocytes activated by lymphocytes or cytokines. Biochem Biophys Res
Commun. 186:1510-4.
Siegbahn, A., A. Hammacher, B. Westermark, and C.H. Heldin. 1990. Differential
effects of the various isoforms of platelet-derived growth factor on
chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest. 85:916-
20.
Sihvola, R., P. Koskinen, M. Myllarniemi, M. Loubtchenkov, P. Hayry, E.
Buchdunger, and K. Lemstrom. 1999. Prevention of cardiac allograft
arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-
derived growth factor receptor. Circulation. 99:2295-301.
Smits, A., M. Hermansson, M. Nister, I. Karnushina, C.H. Heldin, B. Westermark,
and K. Funa. 1989. Rat brain capillary endothelial cells express functional
PDGF B-type receptors. Growth Factors. 2:1-8.
Soriano, P. 1994. Abnormal kidney development and hematological disorders in
PDGF b-receptor mutant mice. Genes dev. 8:1888-1896.
Soriano, P. 1997. The PDGF a-recptor is required for neural crest cell development
and for normal patterning of the somites. Development. 124:2691-2700.
Spritz, R.A., K.M. Strunk, S.T. Lee, J.M. Lu-Kuo, D.C. Ward, D. Le Paslier, M.R.
Altherr, T.E. Dorman, and D.T. Moir. 1994. A YAC contig spanning a
cluster of human type III receptor protein tyrosine kinase genes ?PDGFRA-
KIT-KDR? in chromosome segment 4q12. Genomics. 22:431-6.
Stalmans, I., Y.S. Ng, R. Rohan, M. Fruttiger, A. Bouche, A. Yuce, H. Fujisawa, B.
Hermans, M. Shani, S. Jansen, D. Hicklin, D.J. Anderson, T. Gardiner, H.P.
Hammes, L. Moons, M. Dewerchin, D. Collen, P. Carmeliet, and P.A.
D?Amore. 2002. Arteriolar and venular patterning in retinas of mice
selectively expressing VEGF isoforms. J Clin Invest. 109:327-36.
Sun, T., D. Jayatilake, G.B. Afink, P. Ataliotis, M. Nister, W.D. Richardson, and
H.K. Smith. 2000. A human YAC transgene rescues craniofacial and neural
tube development in PDGFRalpha knockout mice and uncovers a role for
PDGFRalpha in prenatal lung growth. Development. 127:4519-29.
Sun, Y., K. Jin, L. Xie, J. Childs, X.O. Mao, A. Logvinova, and D.A. Greenberg.
2003. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after
focal cerebral ischemia. J Clin Invest. 111:1843-51.
Sundberg, C., M. Ljungstrom, G. Lindmark, B. Gerdin, and K. Rubin. 1993.
Microvascular pericytes express platelet-derived growth factor-beta receptors
in human healing wounds and colorectal adenocarcinoma. Am J Pathol.
143:1377-88.
Swan, D.C., O.W. McBride, K.C. Robbins, D.A. Keithley, E.P. Reddy, and S.A.
Aaronson. 1982. Chromosomal mapping of the simian sarcoma virus onc gene
analogue in human cells. Proc Natl Acad Sci U S A. 79:4691-5.
Tanizawa, S., M. Ueda, C.M. van der Loos, A.C. van der Wal, and A.E. Becker.
1996. Expression of platelet derived growth factor B chain and beta receptor
in human coronary arteries after percutaneous transluminal coronary
angioplasty: an immunohistochemical study. Heart. 75:549-56.
Taverna, D., B. Groner, and N.E. Hynes. 1991. Epidermal growth factor receptor,
platelet-derived growth factor receptor, and c-erbB-2 receptor activation all
promote growth but have distinctive effects upon mouse mammary epithelial
cell differentiation. Cell Growth Differ. 2:145-54.
 PDGF-D, a novel member of the PDGF family
49
Terman, B.I., M.E. Carrion, E. Kovacs, B.A. Rasmussen, R.L. Eddy, and T.B.
Shows. 1991. Identification of a new endothelial cell growth factor receptor
tyrosine kinase. Oncogene. 6:1677-1683.
Ustach, C.V., M.E. Taube, N.J.J. Hurst, S. Bhagat, R.D. Bonfil, M.L. Cher, L.
Schuger, and H.R. Kim. 2004. A potential oncogenic activity of platelet-
derived growth factor d in prostate cancer progression. Cancer Res. 64:1722-9.
Vassbotn, F.S., O.K. Havnen, C.H. Heldin, and H. Holmsen. 1994. Negative
feedback regulation of human platelets via autocrine activation of the
platelet-derived growth factor alpha-receptor. J Biol Chem. 269:13874-9.
Veikkola, T., L. Jussila, T. Makinen, T. Karpanen, M. Jeltsch, T.V. Petrova, H.
Kubo, G. Thurston, D.M. McDonald, M.G. Achen, S.A. Stacker, and K.
Alitalo. 2001. Signalling via vascular endothelial growth factor receptor-3 is
sufficient for lymphangiogenesis in transgenic mice. EMBO J. 6:1223-1231.
Waltenberger, J., L. Claesson-Welsh, A. Siegbahn, M. Shibuya, and C.-H. Heldin.
1994. Different signal transduction properties of KDR and Flt1, two
receptors for vascular endothelial growth factor. J. Biol. Chem. 269:26988-
26995.
Waterfield, M.D., G.T. Scrace, N. Whittle, P. Stroobant, A. Johnsson, A.
Wasteson, B. Westermark, C.H. Heldin, J.S. Huang, and T.F. Deuel. 1983.
Platelet-derived growth factor is structurally related to the putative
transforming protein p28sis of simian sarcoma virus. Nature. 304:35-9.
Westermark, B., and A. Wasteson. 1976. A platelet factor stimulating human
normal glial cells. Exp Cell Res. 98:170-4.
Wiig, H. 1990. Evaluation of methodologies for measurement of interstitial fluid
pressure ?Pi?: physiological implications of recent Pi data. Crit Rev Biomed
Eng. 18:27-54.
Wise, L.M., T. Veikkola, A.A. Mercer, L.J. Savory, S.B. Fleming, C. Caesar, A.
Vitali, T. Makinen, K. Alitalo, and S.A. Stacker. 1999. Vascular endothelial
growth factor ?VEGF?-like protein from orf virus NZ2 binds to VEGFR2
and neuropilin-1. Proc Natl Acad Sci U S A. 96:3071-6.
Witzenbichler, B., T. Asahara, T. Murohara, M. Silver, I. Spyridopoulos, M.
Magner, N. Principe, M. Kearney, J.-S. Hu, and J.M. Isner. 1998. Vascular
endothelial growth factor-C ?VEGF-C/VEGF-2? promotes angiogenesis in
the setting of tissue ischemia. Am. J. Pathol. 153:381-394.
Yamashita, J., H. Itoh, M. Hirashima, M. Ogawa, S. Nishikawa, T. Yurugi, M.
Naito, and K. Nakao. 2000. Flk1-positive cells derived from embryonic stem
cells serve as vascular progenitors. Nature. 408:92-6.
Yancopoulos, G.D., M. Klagsbrun, and J. Folkman. 1998. Vasculogenesis,
angiogenesis, and growth factors: ephrins enter the fray at the border
?comment?. Cell. 93:661-664.
Yang, J.C., L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian,
S.M. Steinberg, H.X. Chen, and S.A. Rosenberg. 2003. A randomized trial of
bevacizumab, an anti-vascular endothelial growth factor antibody, for
metastatic renal cancer. N Engl J Med. 349:427-34.
Yarden, Y., J.A. Escobedo, W.J. Kuang, T.L. Yang-Feng, T.O. Daniel, P.M.
Tremble, E.Y. Chen, M.E. Ando, R.N. Harkins, U. Francke, V.A. Freid, A.
Ulrich, and L.T. Williams. 1986. Structure of the receptor for platelet-
derived growth factor helps define a family of closely related growth factor
receptors. Nature. 323:226-232.
Yarden, Y., W.J. Kuang, T. Yang-Feng, L. Coussens, T.J. Munemitsu, T.J. Dull, E.
Chen, J. Schlessinger, U. Francke, and A. Ulrich. 1987. Human proto-
oncogene c-kit: A new cell surface receptor tyrosine kinase for an
unidentified ligand. EMBO J.
Marko Uutela
50
Yokote, K., Mori, S., Siegbahn, A., Ronnstrand, L., Wernstedt, C., Heldin, C.H.
and Claesson-Welsh, L. ?1996? Structural determinants in the platelet-
derived growth factor alpha-receptor implicated in modulation of
chemotaxis. J Biol Chem, 271, 5101-5111.
Zeng, H., H.F. Dvorak, and D. Mukhopadhyay. 2001. Vascular permeability factor
?VPF?/vascular endothelial growth factor ?VEGF? peceptor-1 down-
modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation,
but not migration, through phosphatidylinositol 3-kinase-dependent
pathways. J Biol Chem. 276:26969-79.
Zhuo, Y., G.W. Hoyle, J. Zhang, G. Morris, and J.A. Lasky. 2003. A novel murine
PDGF-D splicing variant results in significant differences in peptide
expression and function. Biochem Biophys Res Commun. 308:126-32.
Ziegler, B.L., M. Valtieri, G.A. Porada, R. De Maria, R. Muller, B. Masella, M.
Gabbianelli, I. Casella, E. Pelosi, T. Bock, E.D. Zanjani, and C. Peschle.
1999. KDR receptor: a key marker defining hematopoietic stem cells. Science.
285:1553-8.
Ziegler, S.F., T.A. Bird, J.A. Schneringer, K.A. Schooley, and P.R. Baum. 1993.
Molecular cloning and characterization of a novel receptor protein tyrosine
kinase from human placenta. Oncogene. 8:663-670.
Zwerner, J.P., and W.A. May. 2001. PDGF-C is an EWS/FLI induced transforming
growth factor in Ewing family tumors. Oncogene. 20:626-33.
